[go: up one dir, main page]

TW297771B - Method for manufacturing acyclovir transdermal delivery - Google Patents

Method for manufacturing acyclovir transdermal delivery Download PDF

Info

Publication number
TW297771B
TW297771B TW83100632A TW83100632A TW297771B TW 297771 B TW297771 B TW 297771B TW 83100632 A TW83100632 A TW 83100632A TW 83100632 A TW83100632 A TW 83100632A TW 297771 B TW297771 B TW 297771B
Authority
TW
Taiwan
Prior art keywords
acid
acv
drug
ministry
pinene
Prior art date
Application number
TW83100632A
Other languages
Chinese (zh)
Inventor
Yow-Puu Hwu
Pey-Shan Jiang
Original Assignee
Nat Science Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Science Council filed Critical Nat Science Council
Priority to TW83100632A priority Critical patent/TW297771B/en
Application granted granted Critical
Publication of TW297771B publication Critical patent/TW297771B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for manufacturing acyclovir transdermal delivery system, which comprises: 0.1 wt% to 30 wt% (acyclovic,ACV), (Ganciclovir,DHPG), (2,3,-Dideoxyinosine, DDI), Ribaviriv, Amantidine, Vidarbine,Zidovudine ZDV, etc.; 0.05 wt% to 20 wt% enhancers, 2 wt% to 99.95 wt% plasticizers; such as PEG, CMC Na, ethylene glycol (E.G.), enhancers chosen from Ursolic acid, Oleanolic acid, glycyrrhizin (beta)-myrcen, oleic acid, cineole, etc, Pharmaceutical acceptable vehicles such as gel, ointment, folution, suspension, etc.

Description

A6 B6 經濟部中央標準局貝工消费合作社印製 五、發明説明( ) 在本世·纪内病毒爲宮已洗成極大·之定憾,其中不論單 純性疙疹(HSV-1)、肝炎,或後天免疫不全病毒(HIV、 AIDS)都存在著難以治療之現象。而目前已知之抗病毒藥 物可區分爲喊咬拮抗劑、嘌呤拮抗劑、天然生物絵、抗生 素、及麻等類。其中包栝胳克和(Acyclovir,ACV * D1)、 丹希克和(Danciclovir,D3)、阿拉阿(Ara-A,9-冷-D-arabinofuranosyl -9H-purin-6-ainine,D4)、迪敵依(2·, 3|-仍(^<财111〇81脱,001,07)、迪敵和(2|,3|41(^(卿 adnosine,DDA,2',3’-Dideoxy-9-/3-ribofuranosyl-9H -purin-6-amine,D6)、狐克和(Ganciclovir,DHPG,9-( 1,3-D i hydroxy-2-propoxy-methy 1) guan i ne,D2)、卡保 和(Carbovir,D5)、卡敵賓(Cordycepin,D8)、去氧克和 (Deoxyguanosine,D9)、赛塔賓(Cytarabine,Dll)、迪 敵希(21,3'-Dideoxycytidine,DDC,D12)、迪似梯(2·,3· -DidehydrO-2’,3’-deoxythyinidine,DHH,D14)、^#ii* (9- (3-Hydroxy-2-phosphony 1 methoxy 1 propy 1) adenos i ne ,HPMPA,DIO)、西都定(Zidovudine,ZDV,D13)、去氧 梯响淀(Deoxythymidine,D15)、氣破抱喊咬⑵^^⑽!^-5-idoaracytosine,HIAC,D17)、破迪希(5-1〇(3〇-2·-deoxycytidine , IDC,D18)、漠烯脱咬(Bromovinyldeoxy uridine,BVDU,D16)、乙去氧級症(2’-Deoxyu「idine, EDI!,D19 )、三甲氟膽症(5-Trifluor*omethyl-2’-deoxy uridine,F3T,D20)、阿氟梯(l-/S-D-Arabinofur*anosyl thymine,Ara-T,D21)、雷保和(Ribaviriv,D23)、崎佳 (9- (3-Hydroxy-2-phosphonylmethoxy 1 propy l) cyt idinc ,HPMPC D22)、雷保麥(Riboxamide,D24)、阿曼定( Amantidine,D25)、輪曼定(Rimantidine,D26)、都曼定 2 紙張尺度逋用中國國家樣準(CNS>甲4规格(210x297公釐) {請先閲讀背面之注意事項再填窝本頁) •裝 .訂 線 A6B6A6 B6 Printed by the Beigong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economy V. Description of invention () In this world, Kineki virus has been washed away by the palace, and it is a pity that no matter whether it is simple pimple (HSV-1) or hepatitis , Or acquired immunodeficiency virus (HIV, AIDS) are difficult to treat. At present, the known antiviral drugs can be divided into vocal bite antagonists, purine antagonists, natural biological agents, antibiotics, and hemp. Among them, Acyclovir (Acyclovir, ACV * D1), Dansikov (Danciclovir, D3), Ara-A (9-cold-D-arabinofuranosyl -9H-purin-6-ainine, D4), Di Diyi (2 ·, 3 |-still (^ < Cai 111〇81 off, 001, 07), Di Dihe (2 |, 3 | 41 (^ (Qing adnosine, DDA, 2 ', 3'- Dideoxy-9- / 3-ribofuranosyl-9H -purin-6-amine, D6), Fox grams and (Ganciclovir, DHPG, 9- (1,3-D i hydroxy-2-propoxy-methy 1) guan i ne, D2), Carbovir (D5), Cardycepin (D8), Deoxyguanosine (D9), Cytarabine (Dll), Didixi (21, 3'-Dideoxycytidine , DDC, D12), Di Si Ti (2 ·, 3 · -DidehydrO-2 ', 3'-deoxythyinidine, DHH, D14), ^ # ii * (9- (3-Hydroxy-2-phosphony 1 methoxy 1 propy 1) adenosine, HPMPA, DIO), zidudin (ZDovudine, ZDV, D13), deoxythymidine (D15), gas breaking hugs and bites ⑵ ^^ ⑽! ^-5-idoaracytosine, HIAC , D17), Podixi (5-1〇 (3〇-2 · -deoxycytidine, IDC, D18), bromovinyldeoxy uridine (BVDU, D16), ethodeoxy grade Disease (2'-Deoxyu "idine, EDI !, D19), trimethylfluorocholesterol (5-Trifluor * omethyl-2'-deoxy uridine, F3T, D20), afluti (l- / SD-Arabinofur * anosyl thymine , Ara-T, D21), Leibohe (Ribaviriv, D23), Qijia (9- (3-Hydroxy-2-phosphonylmethoxy 1 propy l) cyt idinc, HPMPC D22), Leibaomai (Riboxamide, D24), Amantidine (D25), Rimantidine (D26), and Domandine 2 paper scales using the Chinese national standard (CNS> A4 specifications (210x297 mm) {Please read the precautions on the back before filling Nest page) • Binding. Thread A6B6

請 先 閲 讀 背 面 之 注 意 事 項 再 填* 寫 本 頁 裝 經 濟 部 中 央 標 準 局 Ά X 消 f 合 作 社 印 製 D2 Ganciclovir D3 Detcidovir D 4 VkUrabine DS Carbovir 06 2' 3'- DideoKyadnoitne D 7 2_,3'Dide<nyinotine D · Cordycepin D, Oe〇xy|u«nosine 020 (9-<3· Hydf〇xy*2-pho<phonylmechoiylprop)>i)«dei>〇e>neJ Dll CyUrabtne D12 2* ,3'- DKleonycytidiiK D13 Ztdovtidine D14 Z.3 DideKydro-J^'-deoxyihymidine D15 Deoxythymidine D16 Brom〇viny!deoxyuridine DI7 2'· Ruoro- 5* iod〇4r*cy tosine OlS S-lodo-^-dcoxycyudine 019 Deoxyundine D20 S-Tnilaoromethyl-2'-<le〇]iyundine D21 l*beu - D- Arabinofunnoiylihym ine D22 (9(3Hydroxy-2-phosphonylmethoxy)propyl)cy(»dnKi D23 Ribivirin D24 Riboumide 025 Am»ntidine D26 Rimaniidine D27 Tromanudine D2t Arildone dihydio>9>(2-hy4roaycihoiy)6H-punn-6<one; «eydo-fiunocine9*(13*DihyA〇ty^p*cp〇&y*(neihyl)tu«Aine; 2**mino- l*9-dihydn>*9.(丨 *3)·灿丨)6H-purin>6-one2-((Z· Amino>9H->pttna»-^yl)-meihoxy) ethtnol. deoxytcyckwir 9*beu-D-anib0Mfuran〇iy)*9HiMnne-6-imine;-9-beu· D-irabindTuranocyladenine; «denine «rebinoside Carbocydk Z^’-didehydr^U-dideony 屢uanosine T^'OideoKy^beu-ribofuranocyl^H-punn-e-tmine 2* J'-DNleoxy<9-beu-ribofunno$yl-1,9-dihydn>-^H -purin<6-one T-Deoxyftdcnosine; 9-cordyotpoeid〇idenine (9>(3<Hydn»y-2-phosphony|meihoxyJpropyi)adenosine] 4-Amino>l ·6βΐλ·[>-·ηΒΐηοίυηηο«γ1·2(1 H)-pyrimi<li· none;l-beu-D*trtbino(urenosylcyto$ine,l-beta«cyiosine «rabinoiide ?^'*Oideoxy-4*«mino· I >beul>riboiur>nocyi)>2>(l H)· pyrenidinone I •p-Aado-S^-dideoxy · beu · D-cry ihro-pemofur<nosy)) lhymine;3、Azid<v3'-0eoiyihymidtnf ! •(2t3><iMle^dv〇-3-<ie〇iiy beu-D-eryihro-pemofurano tyl)(hyfnifie $>(2-Brom〇vinyl)-Z-deoxyundine ?.Rooio*5-iodo~4-«mino· l.beu-IX«rab)nofuranosyl. 2(1 H>-pyrimidinone:2·· fluAr〇>5-i〇(io. l«beu-«rftbino> furanosylcytosine 2*.De6xy-5,iod<>>4.Mmnu>l.bcta-D-ribofur«nosy",2· (lH)*pyrimidinone 7-Deoxyuridine; l-(2>deoxy beu-D-eryihro*pentofursiK>· syj)ur»cil; i'(2-deoxy-beu-D-nb〇ruranocyl)urecU; uracil deoxyribosidePlease read the precautions on the back first and then fill in * Write this page to be printed by the Ministry of Economic Affairs Central Standards Bureau Ά X Xiaof Cooperative Printed D2 Ganciclovir D3 Detcidovir D 4 VkUrabine DS Carbovir 06 2 '3'- DideoKyadnoitne D 7 2_, 3'Dide < nyinotine D Cordycepin D, Oe〇xy | u «nosine 020 (9- < 3 · Hydf〇xy * 2-pho < phonylmechoiylprop) > i)« dei > 〇e > neJ Dll CyUrabtne D12 2 *, 3 ' -DKleonycytidiiK D13 Ztdovtidine D14 Z.3 DideKydro-J ^ '-deoxyihymidine D15 Deoxythymidine D16 Brom〇viny! Deoxyuridine DI7 2' · Ruoro- 5 * iod〇4r * cy tosine OlS S-lodo-^-dcoxycyudine 019 Deoxy Tnilaoromethyl-2 '-< le〇] iyundine D21 l * beu-D- Arabinofunnoiylihym ine D22 (9 (3Hydroxy-2-phosphonylmethoxy) propyl) cy (»dnKi D23 Ribivirin D24 Riboumide 025 Am» ntidine D26 Rimaniidine D27 Tromanudine D2t Arildone dihydio > 9 > (2-hy4roaycihoiy) 6H-punn-6 <one; «eydo-fiunocine9 * (13 * DihyA〇ty ^ p * cp〇 & y * (neihyl) tu« Aine; 2 ** mino- l * 9-dihydn > * 9. (丨 * 3) · Can 丨) 6H-purin > 6-one2-((Z · Amino > 9H- > pttna »-^ yl) -meihoxy) ethtnol. deoxytcyckwir 9 * beu-D-anib0Mfuran〇iy) * 9HiMnne-6-imine; -9-beu · D-irabindTuranocyladenine;« denine «rebinoside Carbocydk Z ^ '-didehydr ^ U-dideony repeated uanosine T ^ 'OideoKy ^ beu-ribofuranocyl ^ H-punn-e-tmine 2 * J'-DNleoxy < 9-beu-ribofunno $ yl-1,9-dihydn >-^ H -purin < 6 -one T-Deoxyftdcnosine; 9-cordyotpoeid〇idenine (9 > (3 < Hydn »y-2-phosphony | meihoxyJpropyi) adenosine) 4-Amino > l · 6βlλ · [>-· ηΒΐηοίυηηο« γ1 · 2 (1 H ) -pyrimi < li · none; l-beu-D * trtbino (urenosylcyto $ ine, l-beta «cyiosine« rabinoiide? ^ '* Oideoxy-4 * «mino · I > beul > riboiur > nocyi) > 2 > (l H) · pyenidinone I • p-Aado-S ^ -dideoxy · beu · D-cry ihro-pemofur < nosy)) lhymine; 3, Azid < v3'-0eoiyihymidtnf! • (2t3 > < iMle ^ dv 〇-3- < ie〇iiy beu-D-eryihro-pemofurano tyl) (hyfnifie $ > (2-Brom〇vinyl) -Z-deoxyundine? .Rooio * 5-iodo ~ 4- «mino · l.beu -IX «rab) nofuranosyl. 2 (1 H > -pyrimidinone: 2 · fluAr〇 > 5-i〇 (io. L« beu- «rftbino > furanosy lcytosine 2 * .De6xy-5, iod < > > 4.Mmnu > l.bcta-D-ribofur «nosy ", 2 · (lH) * pyrimidinone 7-Deoxyuridine; l- (2 > deoxy beu-D- eryihro * pentofursiK > · syj) ur »cil; i '(2-deoxy-beu-D-nb〇ruranocyl) urecU; uracil deoxyriboside

DHPGDHPG

Vir«.AVir «.A

Ara-AAra-A

DDA DDIDDA DDI

Alexan; Anbitin; Aracyline, Ara-C; Aracytidine et «1Alexan; Anbitin; Aracyline, Ara-C; Aracytidine et «1

HPMPA An-C ZDV,HPMPA An-C ZDV,

d4Td4T

BVDU FIACBVDU FIAC

IDCIDC

(9-(3-Hydroxy>2<phosphonylmeih〇Aylpropyl)cylidine) l-beU-D-Ribofuranosyl* 1 Η· 1,2,4-tnazole 3-carfoox«midc 2.beu-D*RibofurinosyM.thii2〇lcaboxan)ide: tUzofurin Tricyclo (3.3.1.1) decan l>amine. I «damaruanamine. 1-aminotdamanunr X-Me(hyUricyclo(3.3.l.i|dccan-l-mcthanamine ; x-melhyl· lidamanunmethy timinc Ν.1·Α4νηΜΐ)τΙ-Ν·|2·(4ίτηβϋ))τΙιπιίηο>«ιΚο&χ】《〇€ΐ>ηηι0£ 4.(6-(2*Chloro-4>(neth〇Kyphcnoxy)hexyi|3,5*hcpurx>.-dione N'(Aminoiminon)Cihyl) * mnrph〇luiccarKt\imiJ jmidc; abiiylguamdc 6>((Hyd(〇&yimino)fhcn> i».c:hyl|-l-t< l*mtihylcth>i) sulkmyl|-( 11 l)-hun7.>mt«Jx/oi 2>amii»c Dthydroxyphottphincca^ixlic icid oxide trisoJium sail; Imodium phutphonoloyTiuic_(9- (3-Hydroxy > 2 < phosphonylmeih〇Aylpropyl) cylidine) l-beU-D-Ribofuranosyl * 1 Η · 1,2,4-tnazole 3-carfoox «midc 2.beu-D * RibofurinosyM.thii2〇lcaboxan ) ide: tUzofurin Tricyclo (3.3.1.1) decan l> amine. I «damaruanamine. 1-aminotdamanunr X-Me (hyUricyclo (3.3.li | dccan-l-mcthanamine; x-melhyl lidamanunmethy timinc Ν.1 · Α4νηΜΐ) τΙ-Ν · 2 · (4ίτηβϋ)) τΙιπιίηο > «ιΚο & χ】 《〇 € ll > ηηι0 £ 4. (6- (2 * Chloro-4 > (neth〇Kyphcnoxy) hexyi | 3,5 * hcpurx > .-dione N '(Aminoiminon) Cihyl) * mnrph〇luiccarKt \ imiJ jmidc; abiiylguamdc 6 > ((Hyd (〇 & yimino) fhcn > i ».c: hyl | -l-t < l * mtihylcth > i) sulkmyl |-(11 l) -hun7. > mt «Jx / oi 2 > amii» c Dthydroxyphottphincca ^ ixlic icid oxide trisoJium sail; Imodium phutphonoloyTiuic_

Viramid ei «1. Amazolon: Manudix ei al MeradanViramid ei «1. Amazolon: Manudix ei al Meradan

Hioxim:: Viroml. Virusinm d «I.Hioxim :: Viroml. Virusinm d «I.

F3T Ara-T HPMPC RTCA TCARF3T Ara-T HPMPC RTCA TCAR

ABOB 3 _本紙張尺度適用中B B家樣準(哪)甲4^X210X297公《)ABOB 3 _This paper size is applicable to the B B family sample standard (which) A 4 ^ X210X297 Gong ")

五、發明説明( ) A6 B6 經濟部中夬標準局S工消资合作社印5iV. Description of the invention () A6 B6 Printed 5i by the China Industrial Standards Bureau of the Ministry of Economic Affairs

Cj" roman tad i ne ’ D27)、阿权冬(Aritdone ’ D28)、安吝定 (Horoxydine,D29)、恩輝安(0nviroxime,D30)、弗卡那 (Foscaroct sodium,D31),如表1所示均爲類似结搆之 抗病毒藥物。這些藥物給藥途:徑不外口服、注射、局部塗 敷,而所存在之毒性極高甚至於有抑制中樞神經系紋、腎 姑铋银氦〇 腮克和(ACV)之化學结構式爲含有如圖卜1所示嘌呤 環(Purine)與去氧烏糞核苷(2'-De〇xyguanosine)架構 之9-[(2-Hydroxyethoxy)methyl] Guanine 化合物。聰克 和(ACV)對於第一型及第二型之單純性癌療病毒(hsv 1、 2)、水癌型帶狀绝療病毒(Varicella roster virus,VZV )、艾巴病毒(Epstein barr virus,EBV)以足胞漿病毒( Cytomegalovirus,CMC)均具備抑制作用,而其藥效對於 第一型單純性疱修病毒(HSV 1)較強,其次爲第二型單純 性疱疹病毒(HSV 2)、水痘型帶狀疱疹病毒(腳)、艾巴病 毒(EBV)和胞漿病毒(CMV)然而抑制作用依序遞減。經趙 内實驗技實聰、克和(ACV)治療單純校疮療病毒之效果較象 琪胞喊啶(HIAC)或胍克和(DHPG)爲佳。且可同時對抗單 純性疱疹病毒第二型和第一型,比溴烯膦啶(bromovinyl_ deoxyuridine)更優:異之能力。至於運用腮克和(acv)抑 制水痘型帶狀絶療病毒(VZV)之作用,惟於不同實验中出 現極大差異性之結杲。通常於赠外試验下腮克和(ACV)對 (請先閱讀背面之注意事項再填寫本頁) -裝 訂.....................線......... 本紙張尺度遄用中國國家標準(CNS)甲4規格(21〇Χ297公釐)Cj " roman tad i ne 'D27), Aquandone (D28), Anoxydine (D29), Enviran (0nviroxime, D30), Foscaroct sodium (D31), as shown in Table 1 All shown are antiviral drugs of similar structure. The route of administration of these drugs: oral, injection and topical application, but the toxicity is extremely high and even inhibits the central nervous system lines, the chemical structure of the kidney, bismuth, silver, helium and (ACV) is It contains 9-[(2-Hydroxyethoxy) methyl] Guanine compound with Purine ring and 2'-Deoxyxyguanosine structure as shown in Fig. 1. Cong Kehe (ACV) for type 1 and type 2 simple cancer therapy viruses (hsv 1, 2), water cancer banded anaphylactic virus (Varicella roster virus, VZV), Epstein barr virus , EBV) with Cytomegalovirus (CMC) has an inhibitory effect, and its drug effect is stronger for herpes simplex virus type 1 (HSV 1), followed by herpes simplex virus type 2 (HSV 2 ), Varicella zoster virus (foot), Epstein-Barr virus (EBV) and cytoplasmic virus (CMV). According to Zhao Nei's experimental skills, Satoshi, Kehe (ACV) is better than HIAC or Guankehe (DHPG) in the treatment of simple school sore virus. And it can fight against herpes simplex virus type 2 and type 1, which is better than bromovinyl deoxyuridine: different ability. As for the use of Zac and (acv) to inhibit the varicella zoster virus (VZV), there were very different results in different experiments. Usually under the gift test, the cheek and (ACV) pair (please read the precautions on the back before filling out this page)-binding ..................... line ......... This paper scale adopts the Chinese National Standard (CNS) A4 specification (21〇297mm)

A6 B6 五、發明説明( ) 抗抱漿病毒(CMV)之療效較破膽《定(Idoxuridine)、三氟躲A6 B6 Fifth, the description of the invention () The curative effect of anti-convulsant virus (CMV) is more potent than that of "Idoxuridine, trifluorofluorocarbon"

啶(frifluridine)、維達賓(Vidarabine)或狐克和(DHPG )差些。胳克和(ACV)亦也可抑制艾巴病毒之Productive cycle,惟對於該病毒處於潛伏期則無法呈現效果。腮克 和(ACV)與其它棱^類抗痛毒藥成干摄素併用以對抗也括 胞漿病毒(α丨v)在内之某些癌療病毒具有相乘之效果。 目前市售之胳克和(ACV)軟膏一般使用之基劑有聚乙 婦二酵(polyethylene glycol ’ PEG)、水性冷霜基劑 Olodification aqueous cream)及二甲基亞填(Pimethyl sulfoxide * WfiO)。Corey L.等人於1982 年American J. of Medicine第73卷第326 _334贺報告株用每天局部投 與含5 %腮克和之聚乙烯二醉軚膏4-6次連續5〜7天後 ,其雖可於受疱疹感染之皮膚吸收•然而吸收量極少且其 血衆濃度小於0.023 rag/L幾乎無法測出其量。另Poirror R.Η.等人於該年相同刊物第393茛浞出報告,25個眼睛 有结合後穹窿之病人以含3%腮克和之聚乙烯二酵軚膏每 隔5小時投與一次(每天4-6次),最後一次給藥後5分鐘 内進行内障摘除手街(〔ataract extration),經測定得水 篆液(Aqueous humour)内之聪·克和(ACV)平均濃度爲1.7 mg/L,顯示可得到極高之穿透量。1986年D.J· 等人於J. of Infectious Diseases 第 153 卷第64-70 頁 研究賦形劑對於單位面積上單位時間内腮克和(ACV)局部 製劑之穿透量(Flux) *比較含5%腮克和(ACV)之水性冷 霜基劑(Mod i f i cat i on aqueous cream)、或聚乙稀一薄 (polyethylene glycol * PEG)製劑’以及含6% 胳克和( ACV)之二甲基亞减(DMSO* dimethyl sulfoxide)等3 種 [本紙張尺卢適_)?!中國國家樣承(CNS)f4規格(21()X297公 • 、 5Friduridine, Vidarabine or DHPG are worse. ACV can also inhibit the productive cycle of aba virus, but it cannot show the effect for the virus in the incubation period. Cheek and (ACV) and other analgesic poisons form a dry hormone and are used to fight against certain cancer viruses, including cytoplasmic viruses (α 丨 v), which have a synergistic effect. At present, the bases commonly used in commercially available ACV ointment include polyethylene glycol 'PEG, Olodification aqueous cream and Pimethyl sulfoxide * WfiO. . Corey L. et al., 1982, American J. of Medicine, Volume 73, Nos. 326-334, reported that the strain was locally administered 4-6 times a day with polyethylene biscuit cream containing 5% cheeks for 5 to 7 days. Although it can be absorbed in the skin infected with herpes • However, the amount of absorption is very small and its blood concentration is less than 0.023 rag / L. In addition, Poirror R.Η. et al. Reported in the same publication No. 393 of the same year that 25 patients with a combined posterior fornix were administered once every 5 hours with a polyethylene dizygote cream containing 3% cheek and polyethylene. (4-6 times a day), within 5 minutes after the last dose, cataract extraction (〔ataract extration) was performed, and the average concentration of Satoshi Kehe (ACV) in Aqueous humour was determined to be 1.7 mg / L, showing that a very high penetration can be obtained. In 1986, DJ et al., J. of Infectious Diseases, Volume 153, pages 64-70, studied the penetration of excipients to topical formulations (Flux) per unit time per unit area (Flux) * Compared to 5 % Cheek and (ACV) water-based cold cream base (Mod ifi cat i on aqueous cream), or polyethylene glycol * PEG preparation 'and 6% 克克 和 (ACV) 二甲3 kinds of [DMSO * dimethyl sulfoxide] [this paper ruler Lu Shi_] ?! China National Sample (CNS) f4 specifications (21 () X297 g • 5

裝 1ΤΓ (請先閲讀背面之注意事項再填寫本頁) 標 A6 B6Install 1ΤΓ (please read the precautions on the back before filling in this page) A6 B6

2977,U 五、發明説明( ) 劑型*發現聚乙烯二酵(PEG)之單位面猜上單位時間之穿 透量最小而另兩種劑型分別爲其單位時間穿透量之8倍和 10倍。依據Greg E.等人發表於J.Invest.Dennatol.之 1992年第98卷第856-863頁之研究•發現臨床上治療第 一型單純性疱疹病毒(HSV 1)以口投與聪克和(ACV)之故 果比局部塗敷更好,而患部表皮之藥物瀘度比口投藥減低 2至3倍。且經烀佑(review)已發表之18篇論文征實局 部塗敷方式投與聪*克和(ACV)製#],然而Jfc克和(ACV)並 不能作用於真皮處,此報導飪實目前市售之胳克和(ACV) 軟膏無效。可見發展胳克和(ACV)經皮吸收製劑,以便藥 物能進入較深屑之組織產生療效極具開發意義。本發明係 一種經皮吸收製劑·其係於含抗病毒藥物之習知局部投藥 劑型加入經皮吸收促進劑以改善經皮吸收效應。 經皮輸藥系统乃係一種可產生控制性之藥物輸送系统 (Drug Delivery System) *將其局部塗敷後能持續地、緩 慢地釋出藥物而達於表皮•並使藥物穿透表皮屑進入徵血 管而經循環系统ίι]達治療標的區呈現療效。該類劑型最大 俊黠之處在於使用方便、安全,通常貼於皮膚上或局部投 與•必要時並能隨時撕去不致於發生藥物突然大量釋出超 出臨界劑量之危險性·。一般成年人皮膚總面積约爲2 πι2, 而微企管之血流量約佔全身三分之一,是以近年來經皮輸 藥系统已成爲一種具有相當潛力之給藥途:徑。同時經皮輪 藥系统之設计亦擁有改善或去除一般傳统劑型副作用之優 黠,並可適時適量地釋出藥物以發揮最欠療效,故在竑床 上得到極佳之評價。 -裝 .訂 經濟部中央標準局貝工消费合作杜印製 本紙張尺度璁用t國國家樣準(CNS)甲4规格(210x297公釐) --- Α6 Β6 五、發明説明( ) 然而經皮輸藥系统亦受藥物理化性質,如分配係數、 分子量大小、滾度、分子極性;或是經皮輪藥系统本身的 理化性質,如基劑極性,藥物在基劑之溶解度,系统内組 成成分,基剩黏度;甚至於表受皮膚生理及病理狀沉,如 角質層之错存效應•皮膚表面脂質菝,皮膚水合程皮•皮 膚溫度,塗敷枯貼部位差異性,皮膚外傷,病理傷害和藥 物在皮膚内代謝作用等因素所左右。目前經皮吸收輪藥系 统最普遍之難題在於缺乏強力且安全之經皮吸收促進劑。 近年來醫學十足發展下人們對於東方醫學之評價已明 顯提高,例如1975年就日本厚生省同意將210種中藥複 方運用於國民健康保險。中藥治病所採用方式有汗、吐、 泄、下、托、補、和、解等類複方方劑,調查這些複方之 處方中有150種含有甘莩,其出現頻率佔71,4%爲最高, 其後依序爲生Ϊ佔42.9%、茯苓佔35.2%、芍藥佔32.9% 、大棗佔31.9%、及桂枝佔29.5%等。而另外曰本國民醫 藥品集第二修訂版注解中收載的93種複方處方之出現頻 率甘草仍然最高*第二位是生薑,前面六位順序的生藥與 上述情沉完全相同,而六位以下的的顺序也與運用於國民 健康保險中藥複方之頻率相似。 經濟部中央標準局員工消费合作社印製 (請先閲讀背面之注意事項再填窝本頁) 裝 .4 中藥複方使用頻率較高藥枯之甘革根(glycyrrhizae 丫adix) ’所含之主成分爲甘草Si%lycyrrhizin)、甘草次 睃(分lycyrrhetinic acid)等三萜皂苷结搆(triterpene saponin)。其次之薑(Zingiberis rhizoma),所含主成分 本纸張尺度適用t圉國家標準(CNS)甲4规格(210X297公釐) ST年P; U令止 A6 袖兄 B6 五、發明説明( ) 經 濟 部 t 央 標 準 局 員 工 消 合 作 社 印 製 中以落烯(ot-Pinene)、/5-月桂婦(/3-Myrcene)、桉葉酸 (Cineole)之類精油(Essential oil)爲主。而常用之大 棗(Zizyphi ructus)所含主成分爲齊敗策蔽(0leanolic acid)、熊果酸(Ursolic acid)等三類配號it (triterpenoid) 。 息角治leditsia sinensis |aro.) 中所含主成分 爲牙束答(^ledinin)、莢泉素苷6leditschia saponin ) 等三IS類龙爸及鞣質(Jannins)。茯茶(iloelen)中所含主 成分爲菌乳酸([buricoic acid)、乙随去氛获答酸(3/3-0 •acetyldehydrotumulosic acid)、乙雄获冬酸(3召-〇_ acetyltumulosic acid)、去氣菌孔酸(Pehydroeburicoic acid)、麥角固醇(f rgosterol)之類三萜類急夺。芍藥根 (paeoniae radix)中所含主成分爲巧藥蒼(paeon if lor in )、白芍苷fAlbiflorin)、含氧巧藥苷(ftypaeoniflorin) 、方藥辆(}^01^1〇「丨脚101^)、笨甲酸芍藥芬(61120丫卜 paeonif lorin)、4~ Ί 技没·食子随葡萄 galloylglucose)、反兒茶精((+)- Catechin)、原車細没 食子斑(pV*〇cyanicHn B -1)、單帖類配號始(monoterpene glycoside)等鞣質。桂皮(Ginnamoni cortex et caul is )所含主成分爲桂皮乙酯(Cinnaray 1 acetate)、栓皮醛( Cinnamaldehyde)之類精油成份及·肉枝^0nncassiol A )、氫化桂皮稀嗣吟111^〇]「0(^111^6:/13)1〇1)、去氫桂皮稀寧 Wnhydrocinnzeylanine )、桂·皮稀寧(Cinnzeylanine)、 桂皮烤嗣(Cinnzeylanol)等揉質。 歸纳上述這些藥材之主成分不外單萜類配酷禮、三萜類配链始、三疮類息夺、揉質、精油’而二站類鬼夺本身 8 請 先 閲讀 背 面 之 注意 事 項 再填 窝 本 頁 裝 訂 線 本紙張尺度適用中國國家標準(CNS)甲4規格(210X297公釐1 ,ΐ: Α6 Β6 五、發明説明( ) 具有界面活性劑之性質·可降低皮膚表面張力,協助藥物 經由皮膚到達較深層扭織,增加藥物之穿透及治療故果。 精油、甘草酸和甘草次酸等成分,在艟外试驗拉實均有消 炎作用,其中之甘草酸和甘草次酸更有抑制腳掌腫脹(paw swelling)能力。 1987年Segal R·等人以0.2%填脱啶(IDU)與2%甘 草酸、0.1%安息香酸(Bonzoicacid)之凝膠劍^1)製 劑可口服給藥以治療單純性疮淨(HSV),獲得美國第4,678 ,772號專利。同年Segal R.等人於J.Clinic Phann.第 12卷第1-7頁報告2 %換脈啶(腦)與甘草酸之凝膠劑, 與含5%破脱症之治療緯如松(Viruson)市售軟膏劑比較 治療唇或鼻上單純性抱療之结果,發現前者不僅可缩短癒 合時間,更可降低疼痛感覺。而Touitou E.等人於次年之 Drug Design and Delivery 第3 卷第267-272 頁指出以 完整之裸鼠皮膚於34°C與25°C下進行體外擴散實验,發 現2 %碘膦啶(IDU)與甘草酸之凝膠劑於單位面積上單位 時間之穿透量(^lux)隨環境溫度不同分別爲後者之6倍與 20倍。 經濟部中央標準局員工消费合作社印製 (請先閲讀背面之泫意事項再填窝本頁) 本發明經考慮安全性,於常用之中藥“藥引子M成分 中尋找有效之經皮吸收促進劑。本發明之經皮吸收促進劑 係將抗病毒藥物、中藥“藥引子”添加於嗜霧劍、軟膏劑 (CJintmeirt)、凝膝劑(&el)、溶液剖(|^>lution)、懸浮劑( 本紙張尺度適用中國國家標準(CNS)甲4规格(210X297公釐1 A6 B6 經濟部中央標準局貝工消费合作社印製 五、發明説明(2977, U V. Description of the invention () Dosage form * It is found that the unit surface of polyethylene diacid (PEG) guesses that the penetration per unit time is the smallest while the other two dosage forms are 8 times and 10 times the penetration per unit time respectively . According to the study published by Greg E. et al. In J. Invest. Dennatorl, 1992, Volume 98, pages 856-863. • It was found that clinical treatment of herpes simplex virus type 1 (HSV 1) was administered orally to Congke and (ACV) is better than topical application, and the degree of drug loss on the epidermis of the affected area is 2 to 3 times lower than oral administration. And 18 papers published by 祀 佑 (review) collected the topical application method and applied Satoshi * Gram and (ACV) system #], but Jfc Gram and (ACV) did not work on the dermis, this report is practical Currently available ACV (ACV) ointment is invalid. It can be seen that the development of ACV (ACV) percutaneous absorption preparations so that the drugs can enter the tissues of deeper debris to produce therapeutic effects is of great development significance. The present invention is a percutaneous absorption preparation. It is a conventional topical dosage form containing antiviral drugs. A transdermal absorption accelerator is added to improve the transdermal absorption effect. The transdermal drug delivery system is a controlled drug delivery system (Drug Delivery System) * After it is applied locally, the drug can be continuously and slowly released to the epidermis The area that has reached the treatment target through the vascular system shows the curative effect. The biggest advantage of this type of dosage form is that it is easy to use and safe. It is usually applied to the skin or administered locally. If necessary, it can be torn off at any time so as not to cause the sudden release of a large amount of drugs that exceed the critical dose. The total skin area of an average adult is about 2 π2, and the blood flow of the microenteric tube accounts for about one-third of the whole body. Therefore, in recent years, the transdermal drug delivery system has become a drug route with considerable potential. At the same time, the design of the transdermal medicine system also has the advantage of improving or removing the side effects of the general traditional dosage forms, and can release the medicine in a timely manner and in an appropriate amount to exert the least effective effect, so it has received an excellent evaluation on the bed. -Binding. Binding, Ministry of Economic Affairs, Central Bureau of Standards, Beigong Consumer Co., Ltd. Printed paper, the paper size is used in the National Sample Standard (CNS) A 4 specifications (210x297 mm) --- Α6 Β6 V. Description of invention () However, The transdermal drug delivery system is also affected by the physical and chemical properties of the drug, such as partition coefficient, molecular weight, roll, molecular polarity; or the physical and chemical properties of the percutaneous drug system, such as the polarity of the base, the solubility of the drug in the base, and the composition of the system Ingredients, base residual viscosity; even affected by skin physiology and pathological symptoms, such as the staggered effect of the stratum corneum • Lipid smilax on the skin surface, skin hydration process skin • skin temperature, differences in the application of dry patches, skin trauma, pathology Factors such as injury and drug metabolism in the skin are affected. At present, the most common problem of the transdermal absorption wheel drug system is the lack of a strong and safe transdermal absorption accelerator. In recent years, with the rapid development of medicine, people's evaluation of Oriental medicine has been significantly improved. For example, in 1975, Japan's Ministry of Health, Welfare and Welfare agreed to apply 210 kinds of traditional Chinese medicine to national health insurance. The traditional Chinese medicine treatment methods include sweat, vomiting, diarrhea, down, care, tonic, reconciliation and other compound prescriptions. Among these prescriptions, 150 kinds of prescriptions contain ganji, and the frequency of occurrence is 71,4%. After that, it was 42.9% in raw, 35.2% in Poria, 32.9% in peony, 31.9% in jujube, and 29.5% in Guizhi. In addition, the frequency of appearance of the 93 compound prescriptions contained in the notes of the second revised edition of the Japanese National Medicine Collection is still the highest. The second place is ginger. The first six orders of the raw medicine are exactly the same as the above. The order below the level is also similar to the frequency of the Chinese medicine compound applied to the National Health Insurance. Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the precautions on the back before filling the nest page). 4 The Chinese herbal medicine compound is used more frequently. The main component of glycyrrhizae yaadix is licorice Triterpene saponin (Si% lycyrrhizin), glycyrrhizin (sub-lycyrrhetinic acid) and other triterpene saponin structures. The second is ginger (Zingiberis rhizoma), which contains the main ingredients. The paper size is applicable to the National Standard (CNS) A 4 specifications (210X297 mm) ST year P; U order stop A6 sleeve brother B6 V. Invention description () Economy Essential oils such as ot-Pinene, / 3-Myrcene, and Cineole are the main printing products of the Ministry of Standards and Labor Cooperatives. The main components of the commonly used Zizyphi ructus are 0 (leanolic acid) and ursolic acid (triterpenoid). The main components in leditsia sinensis | aro.) Are three IS-like dragon dads and tannins (^ ledinin), 6leditschia saponin (). The main components contained in eloelen are (buricoic acid), acetyldehydrotumulosic acid (3 / 3-0 • acetyldehydrotumulosic acid), and aspartic acid (3-zhao-〇_acetyltumulosic acid), Triterpenoids such as Pehydroeburicoic acid and frgosterol are rushing. The main ingredients contained in paeoniae radix are paeon if lor in, paeoniflorin fAlbiflorin, ftypaeoniflorin, prescription medicine () ^ 01 ^ 1〇, foot 101 ^), Paeonif lorin (61120 雅卜 paeonif lorin), 4 ~ Ί 技 疊 · 食 子 随 束 galloylglucose), anti-catechin ((+)-Catechin), the original car fine gall plaque (pV * 〇cyanicHn B -1), monoterpene glycoside and other tannins. The main components of cinnamon (Ginnamoni cortex et caul is) are essential oil components such as Cinnaray 1 acetate and Cinnamaldehyde. And · meat sticks ^ 0nncassiol A), hydrogenated cassia cassis 111 ^ 〇) "0 (^ 111 ^ 6: / 13) 1〇1), dehydro cassia cassia thinning Wnhydrocinnzeylanine), gui · piscine (Cinnzeylanine), Cinnzeylanol and other kneading ingredients. The main ingredients of the above-mentioned medicinal materials include the monoterpenes with kurray, the triterpenes with the beginning of the chain, the three sores, the kneading, the essential oil and the second station. 8 Please read the precautions on the back before filling the nest. The gage of this page is in accordance with Chinese national standards (CN S) A4 specifications (210X297mm1, l: Α6 Β6 V. Description of the invention) The nature of surfactants can reduce the surface tension of the skin, assist the drug to reach the deeper layer of twisting through the skin, increase the penetration of the drug and Treating the cause of the disease. Essential oil, glycyrrhizic acid and glycyrrhetinic acid have anti-inflammatory effects in the external test. Among them, glycyrrhizic acid and glycyrrhetinic acid have the ability to inhibit paw swelling. Segal R 1987 · Alternatively, the gel sword with 0.2% dilutidine (IDU), 2% glycyrrhizic acid, 0.1% benzoic acid (Bonzoicacid) ^ 1) preparation can be administered orally to treat simple sore net (HSV) Patent No. 4,678,772. In the same year, Segal R. et al. Reported in J. Clinic Phann. Vol. 12, pages 1-7, 2% gelatin for thymidine (brain) and glycyrrhizic acid, and 5% breakout The treatment of Viruson ointment compares the results of simple lip or supine nasal therapy. It is found that the former can not only shorten the healing time, but also reduce the pain. And Touitou E. et al. Design and Delivery Vol. 3, pages 267-272 indicate that the complete nude skin is at 34 ° C and 25 The in vitro diffusion experiment at ° C found that the penetration amount (^ lux) of the gel of 2% iodophosphoridine (IDU) and glycyrrhizic acid per unit area per unit time (^ lux) was 6 times that of the latter, depending on the ambient temperature. 20 times. Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the back-end notes before filling in the nest page). The present invention considers the safety and finds effective transdermal absorption enhancers in the commonly used Chinese medicine "Medicine Primer M" The transdermal absorption enhancer of the present invention is to add antiviral drugs, Chinese medicine "medicine primers" to the fog fog sword, ointment (CJintmeirt), coagulant (& el), solution profile (| ^> gtution) 、 Suspending agent (This paper scale is applicable to China National Standard (CNS) A4 specifications (210X297 mm 1 A6 B6 Printed by Beigong Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs

Suspension)、貼劑等局部投藥製劑。上迷中藥“藥引子” 除包括甘草、生Ϊ、茯苓、芍藥、大棗,及桂枝等6種中 藥之單一成份外,尚可包含單萜類配疏趙、三辂類配疏趙 、三萜類皂苷、鞣質、精油。由於含皂素植物有50姻_ 科400種植物•經篩選中藥複方方劑中後選用涵蓋 丨伞利j ,3所示f用於中藥複方方劑中之枝物皂素、鞣質、$油 或萜類中藥“藥引子”。 可作爲本發明經皮吸收劑之抗病毒藥物包栝腮克和( ACV)、和其他结構類似均爲核苷(nucleoside)之藥品如圖 >2所示,腮克和(M)、胍克和(D2)、丹希克和(D3)、阿 拉阿(D4)、卡保和(D5)、迪敵和(D6)、迪敵依(D7)、卡敵 賓(D8)、去氧克和(D9)、磷佳和(D]0)、赛塔賓(D11)、迪 敵希(D12)、西都定(M3)、迪似梯(D14)、去氧祥嘧啶 (D15)、溴烯躲啶(D16)、氟碘胞嘧啶(D17)、碘迪希(D18) 、乙去氧肠啶(D19)、三甲氟脲咬(D20)、阿氟梯(D21〉、 磷佳希(D22)、雷保和(D23)、雷保麥(D24)、阿曼定(D25) 、輪曼定(D26)、都曼定(D27)、阿拉冬(D28)、安芬定 (D29)、恩輝安(D30)、弗卡那(D31) 〇其中最適宜製成經 皮吸收劑之藥物爲腮克和(ACV,D1)、胍克和(DHPG,D2) 、阿拉阿(Ara-A,D4)、三甲氟膦啶(F3T,1)20)、氟破抱 嘧啶(HIAC,D17)、溴烯膦啶(BVDU,D16)。 10 本紙張尺度適用中國國家標準⑷昍)甲4规格βαχ297公釐) ............................................................................^......................•玎.....................線 (請先閲讀背面之注意事項再填窝本頁)Suspension), patch and other local administration preparations. In addition to the single ingredients of 6 kinds of traditional Chinese medicines including licorice, raw yip, poria, paeonia, jujube, and twigs, the "medicine primer" of the traditional Chinese medicine of Shangmi can also contain Triterpenoid saponins, tannins, essential oils. Since the saponin-containing plants have 50 marriages_ 400 plants in the family. After screening Chinese herbal compound prescriptions, they are selected to cover the umbrella j j. 3 shown in f is used for the branches of saponin, tannin, $ oil or in the Chinese herbal compound prescriptions. Terpene Chinese medicine "medicine primer". The antiviral drugs that can be used as the transdermal absorber of the present invention include Tobacco (ACV), and other drugs with similar structures that are nucleoside (Fig. 2). Kehe (D2), Dansikhe (D3), Araa (D4), Kabaohe (D5), Didihe (D6), Didiyi (D7), Kadibin (D8), deoxygenation Kehe (D9), Phosphora (D) 0), Setabin (D11), Didixi (D12), Cidudine (M3), Disimidine (D14), Deoxypyrimidine (D15) , Bromophenone (D16), fluoroiodine cytosine (D17), iodix (D18), etodexamine (D19), trimethoprim (D20), aflutide (D21>, phosphazepine Greek (D22), Leibohe (D23), Leibomai (D24), Omandine (D25), Rummandine (D26), Domandine (D27), Aradon (D28), Afindine (D29) ), Enhuian (D30), Fulcana (D31) 〇The most suitable drugs for making transdermal absorbers are cheek and (ACV, D1), guanke and (DHPG, D2), Ara (Ara -A, D4), trimethyl phosphinopyridine (F3T, 1) 20), fluoropyrimidine (HIAC, D17), bromophosphine (BVDU, D16). 10 The scale of this paper is in accordance with Chinese National Standard ⑷ 昍) A 4 specifications βαχ297 mm) ..................................... ...................................... ^ ..... ................. • 玎 ........................ (Please read the precautions on the back first Fill this page)

Α7 Β.7 五、發明説明() 本發明之經皮吸收促進劑係於f知之局部投藥劑型, 如軟膏劑、懸浮劑、凝膠劑、溶液劑、貼劑、喷霧劑中添 加入0.1〜30%之抗病毒藥爲主成份。其中腮克和(ACV)、 溴烯躲症(Bromoviny丨deoxyur丨dine)、狐克和(DHPG)、維 達賓(Vidarabine)、三氣腿症tfrifluridine)、三甲氟級 啶(F3T)、氟破抱嘧啶(HIAC)之含量以0.1〜〗〇%爲最適 宜。不論任何劑型所添加之賦形劑以95%爲宜; 含5% 次乙基乙二醇(EG,ethylene glycol)、42.5〜45% 聚乙稀二醇(PEG 400,poly fythylene glycoO 及42.5〜 45%聚乙烯二醇(PEG 4000)可製成軟膏劑。凝膠劑蝮運 用之賦形劑選自羧酸甲基酯織維素鈉(QC Na)、聚乙烯二 醇(PEG)、甘油glycerin)、次乙基乙二醇(EG)可呈現爲 三種類型;各類型除水份宜保持適量外,第一類型以含2 〜6%之幾酸曱基酿纖维素納(Carboxyroethyl cellulose sodium ’ CMC Na)且配合50% 甘油 glycerin)爲主;第二 類塑以含2〇%次乙基乙二醇(EG * ethylene glyco])配合 2%羧酸曱基酯織維素钠(CMC Na)爲主;第三類型以僅含 20%之次乙基乙二醇(EG)爲主。而懸浮劑以含有50〜9δ %次乙基乙二醇(EG)及適量水份所組成,另外溶波劑以 足夠之水份以超音波振盪器使其完全溶解混合。各劑型中 促進劑之含量以〇·〇5%至20%爲氟圍,最適宜之含量爲 0.1% 至δ%。 本發明”抗病毒藥腮克和(ACV)經皮吸收製劑,,係一 種含藥引子之腮克和(ACV)經皮吸收醫藥組合物,其中包 _iiL·^_ ——J-----{装------訂 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(2^VX:297公^'广·.、Α7 Β.7 V. Description of the invention () The percutaneous absorption enhancer of the present invention is added to the local administration type known as f, such as ointment, suspension, gel, solution, patch, spray, etc. 0.1 ~ 30% of antiviral drugs are the main ingredients. Among them, gram and (ACV), bromoviny (deoxyur 丨 dine), fox and (DHPG), vidabine (Vidarabine), tfrifluridine, trimethylfluoropyridine (F3T), fluorine The content of HIAC is most suitable from 0.1% to 0.1%. Regardless of the excipients added in any dosage form, 95% is appropriate; Contains 5% ethylene glycol (EG, ethylene glycol), 42.5 ~ 45% polyethylene glycol (PEG 400, poly fythylene glycoO and 42.5 ~ 45% polyethylene glycol (PEG 4000) can be made into an ointment. The excipient used in the gel agent is selected from the group consisting of carboxylic acid methyl ester oryzae sodium (QC Na), polyethylene glycol (PEG), glycerin glycerin) and ethylene glycol (EG) can be presented in three types; in addition to keeping the appropriate amount of water in each type, the first type contains 2 to 6% carboxyroethyl cellulose sodium 'CMC Na) with 50% glycerin); the second type of plastic contains 2% ethoxyethylene glycol (EG * ethylene glyco) with 2% carboxylic acid methyl ester oryzanol sodium (CMC Na); the third type is mainly composed of 20% ethylene glycol (EG). The suspending agent is composed of 50 ~ 9δ% ethylene glycol (EG) and an appropriate amount of water. In addition, the wave dissolving agent is sufficiently dissolved and mixed with an ultrasonic oscillator with sufficient water. The content of the accelerator in each dosage form is from 0.05% to 20% as the fluorine circumference, and the most suitable content is 0.1% to δ%. The "antiviral drug Shikehe (ACV) percutaneous absorption preparation of the present invention is a medicine composition containing Zhikehe (ACV) percutaneous absorption pharmaceutical composition, which includes _iiL · ^ _ ——J --- -{Install ------ ordered (please read the precautions on the back before filling out this page) The paper standard printed by the Employee Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs is applicable to the Chinese National Standard (CNS) A4 specification (2 ^ VX : 297 Gong ^ 'Guang ·.,

五、發明説明( 組直立式且上下可分離之雙層玻璃容器。其下層容器充填 合有抗生素之定量0.15 N氣化钠水溶液•底部故置磁石 以產生600 rpm之撥拌效策。内外壁間之炎層以循環水流 維挣板定溫度。上層容器内放置0.25 g或〇.5 g不同劑型 之檢品*上端開口處以保鮮膜從蓋之。上、下二;|間失入 各實验所需之勤物或人類皮膚作爲麥透障壁,並利用金屬 固史失加以固定。於指定時間内由取樣口 (义^丨邱敗代 )抽取200 “L之氣化钠溶液樣品,並立即添加200 uL氯 化鈉溶液於容器内•以維持固定溶液量。每次所抽取之樣 品再加入2〇〇 wL、5 wg/ml之乙酿按敌(Acetaminophen) f爲疗多標準品.以高壓液態廣析法(HPLC)分析檢品之含 換料鮮之技量,⑽料細中主 (犄先«讀背面之注意事項再填窝本頁) •装. •订 .線. 經濟部t央標準局霣工消fr合作社印製 本紙張尺度迠用中Β Β家樣準(CNS)甲4规格(210x297公5. Description of the invention (Group of upright and detachable double-layer glass containers. The lower container is filled with a quantitative 0.15 N vaporized sodium aqueous solution filled with antibiotics. • A magnet is placed at the bottom to produce a mixing effect of 600 rpm. The inflamed layer in the middle is circulated with water to maintain the temperature. The upper container is placed with 0.25 g or 0.5 g of different dosage forms. * The upper opening is covered with plastic wrap from the top. The upper and lower two; The material or human skin required for the inspection is used as the barrier for the wheat penetration, and it is fixed by the use of metal solid history. A sample of 200 liters of vaporized sodium solution is taken from the sampling port (Yi ^ Shu Qiudai) within the specified time, and Immediately add 200 uL of sodium chloride solution to the container to maintain a fixed amount of solution. Each sample taken was then added 200wL, 5 wg / ml of Acetaminophen f as a multi-standard product. The high-pressure liquid wide analysis method (HPLC) is used to analyze the quality of the inspection products containing fresh materials, ⑽ the material is in the main (how to read the precautions on the back and then fill the nest page) • Install. • Order. Line. Ministry of Economic Affairs Printed on paper by the Central Standards Bureau, Fei Gongxiao fr Cooperative Society (CNS) A 4 size (210x297 well

A6 B6 料m ::正 —一 十径 五、發明説明() 爲了判斷製劑中抗病毒藥物經過72小時之體外經皮 穿透试狯後*是否部分藥物枝皮膚之酵素代谢•或實驗過 程存在著足以導致藥物損失之炔陷,而以下列公式计算 A'total R% =-- χ 100¾ A total A'total = A'donor + A'skin + A'receptor A total = A donor R :藥物回收率 A total ••實驗前總藥量 A donor :實驗前供給相之藥量 A'total :實驗後總藥量 A · donor*:實驗後供給相内殘餘藥量 A’skin :實驗後皮膚部位所含有之藥量 A ’receptor :實驗後接受相之藥量 本發明分別選擇孕婦分挽時取下之羊暖,或蛇全皮、 25曰、80曰齡荷蘭豬((guinea pig)之皮膚以及蹲性7 至9週欠之ICR或Balb/C種楳藏(Mudemice)之腹部皮 膚作爲試验皮膚(暖)材料,以研究抗病毒藥物與中藥“藥 引子”製成經皮吸收劑之經皮吸收情形,並以高壓液態層 析法(HPLC)分析定量抗病毒藥物之穿透量。此外’以家兔 ....................................................................................._....................,玎.....................線 <請先閲讀背面之注意事項再填寫本頁一 經濟部中央標準局員工消费合作社印製 本紙張尺度適用中國國家標準(CNS)甲4规格(210X297公釐) gr 年 綠·A6 B6 Material m :: Positive—Ten Diameters Fifth, Description of the Invention () In order to determine whether the antiviral drug in the preparation has undergone a 72-hour in vitro transdermal penetration test, whether the enzyme metabolism of some of the drug ’s skin or the experimental process exists The acetylene trap is sufficient to cause the loss of drugs, and the following formula is used to calculate A'total R% =-χ 100¾ A total A'total = A'donor + A'skin + A'receptor A total = A donor R: drug recovery Rate A total • The total dose before the experiment A donor: the amount of the drug supplied to the phase before the experiment A'total: the total amount of the drug after the experiment A donor *: the residual amount of the drug after the experiment A'skin: the skin area after the experiment Contained dose A'receptor: the dose of the received phase after the experiment. The present invention selects the sheep's noodles that were removed when pregnant women were split, or the skin of whole snake skin, guinea pigs at 25 and 80 And the abdominal skin of ICR or Balb / C Mudmice owing to squatting for 7 to 9 weeks is used as the test skin (warm) material to study the experience of transdermal absorbers made by antiviral drugs and Chinese medicine "medicine" Skin absorption, and quantify the penetration of antiviral drugs by high-pressure liquid chromatography (HPLC) Volume. In addition to 'rabbit ................................................. ...................................._....... ............., 玎 ..................... Line < Please read the notes on the back before filling this page 1. The paper printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs applies the Chinese National Standard (CNS) A4 specifications (210X297 mm) gr year green.

.\L I Ή A6 B6 經濟部中央樣準局員工消ff合作社印製 五、發明説明( ) 進行殖内實驗,捋藥物羡蓋於家兔耳朵經72小時後測定 該耳朵各層皮層之胳克和及組織中藥物浪度。本發明製劑 經趙外實驗轻現中藥“藥引子”有促進經皮吸收玫果,例 如含0.01%甘草酸合lycyrrhizin)製成之0.01%胳克 和(ACV)水溶波處方(#1)製劑經過28.75小時的蛇皮趙外 穿透试驗,如圖3所示其面積穿透累積量4.8 ag/Cm2 爲不含甘草酸控制組處方(似)之2倍。若於含2%羧酸甲 基酯漩雉素钠(CMC糾爲基劑之2 %腮克和(ACV)凝膝劑 ,分別使用80日齡、25日齡荷蘭豬豬皮*及7至9遇大 之母棵II史比較經皮吸收效策,72小時後如圖4所示裸 鼠皮穿透效策較好;而羊暖或80日齡、25日齡之豬皮其 於路克和_經皮吸收效應都很差。 目前市售含腮克和(ACV)之軚膏常使用基劑有聚乙烯 二醇(PEG)、水性冷霜基劑(modification aqueous cream )及二甲基亞(dimethyl sulfoxide,DtSO)。本發明改 用2%羧酸甲基酯線維素钠(CMC Na)爲基劑製成凝膝劑, 以改善聚乙烯二醇(PEG)爲基劑所造成經皮吸收效策不佳 之現象。如圖5所示,比較此兩種製劑經過72小時之 試驗,其單位面積之穿透累積量依次爲34.9 Mg/cm2與 -5.3叫/〇112,以2%羧酸曱基酯織維素钠(〇£如)爲基劑 製成之凝膠劑比以聚乙烯二醇(PEG)爲基劑之坎膏可達到 7倍更好之經皮炎收結果。而且即使於聚乙烯二醉(pEG) 基创之軟资中加入不同含量之甘草酸丨2 i η),經 體外穿透試驗後亦無法在统计上呈現有意義之差別,顯示 添加甘草駿於聚乙烯二醇软膏中甘萆酸仍無法發揮促進經 ......................................................................................裝......................訂.....................線 {椅先閲讀背面之注意事項再填客本頁) 本紙張尺度適用中圉國家標準(CNS)甲4規格(21〇Χ297公釐 :-—~~一. \ LI Ή A6 B6 Printed by the staff of the Central Provincial Bureau of the Ministry of Economic Affairs Cooperative Society V. Description of the invention () Conducted an intra-colonial experiment, the drug was encased in the ears of rabbits, and the cortex and cortex of the ears were measured after 72 hours And the wave of drugs in the organization. The preparation of the present invention shows that the traditional Chinese medicine "Medicine Primer" has been promoted by Zhao Wai's experiment to promote percutaneous absorption of rose hips, for example, 0.01% gram and (ACV) water-soluble wave prescription (# 1) preparation made with 0.01% glycyrrhizin and lycyrrhizin). After 28.75 hours of snake skin Zhao external penetration test, as shown in Figure 3, the cumulative area penetration of 4.8 ag / Cm2 was twice (previously) the prescription of the control group without glycyrrhizic acid. If using 2% carboxylic acid methyl ester sodium pheasant sodium (CMC correction base 2% cheek and (ACV) knee coagulant, use 80-day-old, 25-day-old guinea pig skin * and 7 to 7 The history of the 9-year-old mother tree II compares the percutaneous absorption strategy. After 72 hours, as shown in Figure 4, nude skin penetration strategy is better; and sheep warm or 80-day-old, 25-day-old pig skin is better Ke and _ percutaneous absorption effects are very poor. At present, the commercially available bases containing cheek and (ACV) commonly used bases are polyethylene glycol (PEG), aqueous cold cream base (modification aqueous cream) and dimethyl Dimethyl sulfoxide (DtSO). In the present invention, 2% carboxylic acid methyl ester sodium CMC sodium (CMC Na) is used as a base to make a knee coagulant to improve the polyethylene glycol (PEG) as a base. The phenomenon of poor transdermal absorption effect. As shown in Figure 5, comparing the two preparations after 72 hours of testing, the cumulative penetration per unit area is 34.9 Mg / cm2 and -5.3 called / 〇112, with 2 % Carboxylic acid methyl ester oryzanol sodium (££) as a base gel made of polyethylene glycol (PEG) as a base can achieve 7 times better percutaneous inflammation results . And even if the two are drunk with polyethylene pEG) Adding different amounts of glycyrrhizic acid in the soft foundation of KIC (2 i η), after an in vitro penetration test, there is no statistically significant difference, showing that the addition of glycyrrhizic acid in polyethylene glycol ointment still results in a glycyrrhizic acid Unable to play promotion script ........................................... ....................................... install ... ............. Booking ..................... line (chair read the notes on the back first and then fill out this page) The size of this paper is applicable to China National Standard (CNS) Grade A (21〇297297mm: --- ~~ 1

五、發明説明( A6 B6 皮吸收之效果。然而以2¾羧酸甲基酯纖維素^(CMCt(a) 爲基劑之凝膠劑中加入甘萆酸•今I圖6所示•其單位面 積穿透累積量在统訐上明顒有意義之差别,然而此類凝膠 中甘草酸添加比率髙於2¾時反而又與控制組没有统计上 有意義之差別性。顯示甘草酸之穿透促進效應作用機轉有 劑量依赖(Dose dependent)之現象。 以2 %羧酸曱基酯織維素钠(CMC Na)爲基劑之凝膝劑 ,分別選擇不同種類不同比例之中藥《藥引子《作爲經皮 吸收促進劑如於蜗萵花、擷草根、薄荷、紫蘇葉、大棗、 胡椒、厚朴、辛夷、白豆蔻、莪朮、薑、香附子、番紅花 所含之(⑸-蔽歸[Qs)-㈠-a -pinene];於熊杲葉、山 策焚、大棗中所含之熊策酸(Urs〇Hc acid);於中甘草所 合之 18-甘草次厶-glyCyrrhetinic acid)、甘草酸 (々lycyrrhizin);於連翹、山菜萸、丁香、大棗所含之齊 漱采酸(Oleanolic acid);於辛夷、鬱金及番紅花所含之 按"葉素(Cineole);於茴香、肉豆蔻所含之(+)-¾焊(α-( O-pinene);於栓皮、白朮、當歸、Ρ東皮、川芎、美遠志 、茵陳蒿、洋甘菊、木香、荆芥、茴香、丁香、桉葉、枳 實、吳策萸、花板、細辛、蕺菜、五味子、益智仁、缩砂 所含之精油;於澤瀉、甘遂、西黄耆膠、祧仁、升麻、桑 白皮所含之二帖類皂|(triter.pene saponin);於忽布、 白豆兹及1所含之>]枝稀(点-;於息角、苟藥、 桂皮及大黄等成分之鞣質(丁annins);經過實驗於72小時 單位面積各製劑之穿透累積量如圖7所示,依次處方 (并 1)爲 605-3 ug/cm2、處方⑽)爲 206.4 wg/cra2、 - f I ......................................................................................^......................-玎.....................^ {請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印奴 本紙張尺度遇用中國國家標準(CNS)甲4規格(210x297公釐)V. Description of the invention (The effect of A6 B6 skin absorption. However, the gelling agent based on 2¾ carboxylic acid methyl ester cellulose ^ (CMCt (a) as the base agent is added with aglycolic acid. The cumulative amount of area penetration is statistically significant, but the addition rate of glycyrrhizic acid in such gels is higher than 2¾, but there is no statistically significant difference from the control group. The penetration promoting effect of glycyrrhizic acid is shown. The mechanism of action is dose-dependent (Dose dependent). The knee coagulant with 2% carboxylic acid methyl ester oryzanol sodium (CMC Na) as the base agent, respectively selects different kinds of different proportions of traditional Chinese medicine "medicine" as Transdermal absorption enhancers such as snail lettuce, grass root, mint, perilla leaves, jujube, pepper, Magnolia officinalis, Xinyi, white cardamom, zedoary, ginger, fragrant monkshood, saffron (⑸-Maogui [ Qs) -㈠-a-pinene]; Urs〇Hc acid (Urs〇Hc acid) contained in Xiongcao leaves, Shanceen, and jujube; 18-glycyrrhizin-glyCyrrhetinic acid combined in Chinese licorice) , Glycyrrhizic acid (々lycyrrhizin); oleanolic acid contained in forsythia, cornel, clove, and jujube ); Pressed by "Cineole; contained in Xinyi, turmeric and saffron; (+)-¾ weld (α- (O-pinene) contained in fennel, nutmeg; in cork, Atractylodes, Angelica , P Dongpi, Chuanxiong, Meiyuanzhi, Yinchenhao, Chamomile, Woody, Nepeta, Fennel, Clove, Eucalyptus, Fructus Aurantii, Fructus Corni, Flower Board, Asarum, Ivy League, Schisandra, Yi Zhi Ren The essential oil contained in the sand; the two post-type soaps contained in Yu Zexi, Kansui, West Yellow Tengjiao, Zhiren, Cimicifuga, Sangbaipi | (triter.pene saponin); Yuhubu, Baidouzi and 1 contained>] twigs (point-; tannins in ingredients such as dips, medicinal herbs, cinnamon and rhubarb); the cumulative amount of penetration of each preparation in a unit area of 72 hours after the experiment is shown in Figure 7 As shown, the prescription (and 1) is 605-3 ug / cm2, and prescription ⑽ is 206.4 wg / cra2,-f I ..................... .................................................. ............... ^ .........................- 玎 .......... ........... ^ {Please read the precautions on the back before filling out this page) The paper standard of the printed copy of the printed copy of the employee consumer cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs China National Standard (CNS) Grade 4 specifications (210x297 mm)

五、發明説明( 2 A6 B6 處方(ίί3)爲 186.0 以g/cm2、處方(料)爲 173.1 wg/cm 處方(#5)爲 125.5 "g/cm2、處方(他)爲72.5 M/cm2、 處方(#7)爲 61.0 以 g/cm2、處方(胳)爲 54.5 “g/cm2、 處方(的)爲53.4 wg/cm2;與圖5中聚乙烯二酵(PEG )爲基劑軚膏之72小時單位面猜穿透累積量5.3M/cm2 加以比較可發現® 7各製劑之穿透累積量增加量依序爲 114 倍、38.9 倍、35 倍、32.6 倍、23.6 倍、13·7 倍 、:11.5倍、10.3倍、10.8倍。其中以含2%甘草酸之處 方(#1)及2%齊敗果酸(Oleanolic acid)之處方0®可 產生最大之穿透效應。若於2%腮克和(ACV)凝膝劑之製 劑中以含2%甘萆酸促進劑之處方(0)爲基礎分別洛加其 他促進劑如處方(ttl)添加1 %齊敗策酸、處方(奶)幕加 1 %熊果酸、處方(他)添加5 %殖歸、處方(们)添加20 % 二甲基亞(pimethyl sulfoxide ’ DFBO).以及於含 2% 甘莩酸之2 %烙克和(ACV)懸浮劑處方0®進行比較;結 果如圖8所示,72小時後各處方單位面猜穿透累猜量依 次爲2687.7/^/〇112、594.4 /^/<:1112、449.5)^/<:1112、 221.5wg/cm2、Π8.6 "g/cm2、241.0“g/cm2 ;與圖 5 中聚乙烯二醇(PEG)爲基劑軟膏之72小時單位面積穿透累 積量5.3//s/cm2加以比較可發現圖8各製劑之穿透累 植量增加量依序爲507倍、112倍、85倍、41.8倍、 22.4倍、45.5倍,其中以含齊漱果酸(Oleanolic acid)之處方(ίίΐ)可產生最大之穿透效應。 此外,於含2 %甘莩酸之2 %腮克和(ACV)凝膝劑分 別添加1%如)及2% (符2)之息角(红leditsia sinensis 本紙張尺度適用中國國家標準(CNS)甲4規格(210X297公釐.) .................................................-:…-............................裝......................訂.....................線.......... (請先閲讀背面之注意事項再填窝本頁) 铿濟部中央標準局員工消费合作社印製 / h .«4 -WA; ϊ 7 7 Vi A6 B6 —__$!妇.j匕 五、發明説明() I am.)抽提谈,與不含皂角控制組處方Μ)比較72小時 之始外穿透试狭·结采如Β 9所示•處方0»1 · 2)之單 位面積穿透累積量依次爲2523.9/ig/cm2、1158.9ug/cro2、 221.5 as/crn2 ;如前所述方式經與聚乙烯二醉(PEG)軟 胥比較各處方單位面積穿透累積量依序增加爲476.2倍、 218.6倍、41.8俦。顯然皂角可促進腮克和經皮吸收而 其中以1%皂角抽從液JL有效。而且如圖1〇所示即使捋 上述處方(林2)改用1%齊漱茱酸(Oleanolicacid)代替 •比較含1 %齊敗果酸之處方(#1)與含1 %皂角柚提液之 處方¢2)發現二者之經皮吸收效果一樣好,證實皂角抽提 液係極佳之經皮吸收促進劑。如圖11所示•將藥物氣蓋 於家兔耳朵之所進行之勤物賞驗,經72小時後測定該寻 朵各層皮層之胳克和(ACV)濃度,如圖11所示,促使藥 物穿透角質層之程度以含2%甘草酸處方on)之效策最欠 •單位面積穿透累積量爲389.8 zig/cro2 ;而於表皮層、 真皮層以添加1 %齊敗策酸及2 %甘萆酸之處方〇»2)最好 ,單位面猜穿透累猜量爲389.8 wg/cm2 ;。如圖12所 示各組織中藥物之濃度,不論含2 %甘草酸之2 %烬克和( ACV)凝勝劑處方(ttl)*或於其中再添加1 %齊漱果酸之處 方(tf2)兩者製劑如中濃度均有顯著增加現象,前者於72 小時累積量爲0.53土0.02 /ig/mi保無從進劑處方(料)對 照組累猜量爲0.35士0.03 wg/ml效采之1.5倍,而後者 0.48±0.03 "g/ml爲對照組之1.4倍。此外•經測定家 兔各種臟器内腮克和(ACV)之血中濃度,發現含2 %甘草 酸之2%羧酸甲基酯纖維素鈉(QC Na)處方Oil)於叶臟 之含量爲各種臟器之最達6.89士0.38 wg/g僅比對照組 本紙張尺度遴用中國國家標準(CNS)f 4规格(210x297公釐1 ' 门 ^ ...................................................................................裝......................訂.....................線 <請先閏讀背面之注意事項再填窝本頁) 經濟部中央標準局員工消费合作社印製V. Description of invention (2 A6 B6 prescription (ί3) is 186.0 g / cm2, prescription (material) is 173.1 wg / cm prescription (# 5) is 125.5 " g / cm2, prescription (other) is 72.5 M / cm2 , Prescription (# 7) is 61.0, with g / cm2, prescription (54.5) g / cm2, prescription (of) 53.4 wg / cm2; and polyethylene dizygase (PEG) as the base cream in Figure 5 The cumulative amount of penetration per hour in the 72-hour unit surface is 5.3M / cm2. It can be found that the increase in the cumulative amount of penetration of each formulation is 114 times, 38.9 times, 35 times, 32.6 times, 23.6 times, 13.7 Times,: 11.5 times, 10.3 times, 10.8 times. Among them, 2% glycyrrhizic acid (# 1) and 2% oleanolic acid (Oleanolic acid) 0 0 can produce maximum penetration effect. In the formulation of 2% cheek and (ACV) knee coagulant, based on the prescription (0) containing 2% glycofuric acid accelerator, add other accelerators such as prescription (ttl) and add 1% azilosacid, prescription (Milk) 1% ursolic acid in the curtain, 5% colonization in the prescription (he), 20% pimethyl sulfoxide (DFBO) in the prescription (we), and 2% containing 2% glycolic acid Roche and (ACV) Suspension Prescription 0® are compared; the results are as As shown in 8, after 72 hours, the cumulative guessing amount of each unit surface is 2687.7 / ^ / 〇112, 594.4 / ^ / <: 1112, 449.5) ^ / <: 1112, 221.5wg / cm2, Π8 .6 " g / cm2, 241.0 “g / cm2; compared with the cumulative penetration of 5.3 // s / cm2 in 72 hours per area of polyethylene glycol (PEG) as the base ointment in FIG. 5 can be found in FIG. 8 The increase in penetration penetration of each preparation was 507 times, 112 times, 85 times, 41.8 times, 22.4 times, and 45.5 times in sequence. Among them, the place containing oleanolic acid can produce the largest wear. Through effect. In addition, add 2% cheek and (ACV) knee coagulant containing 2% glycylic acid and 1% () and 2% (character 2) of the angle of interest (red leditsia sinensis). The paper scale is applicable to the Chinese national standard (CNS ) A 4 specifications (210X297 mm.) .............................................. .........-: ...-......................... Pretend ... ............. Order ............................................. (please first Read the precautions on the back and fill this page) Printed by the Employee Consumer Cooperative of the Central Standards Bureau of the Ministry of Economy and Economy / h. «4 -WA; ϊ 7 7 Vi A6 B6 —__ $! 女 .jagger V. Description of invention () I am.) Extraction talk, compared with the prescription without saponin control group M) The external penetration test at the beginning of 72 hours is narrowed. The results are shown in B 9. Prescription 0 »1 · 2) The cumulative penetration per unit area The amount is 2523.9 / ig / cm2, 1158.9ug / cro2, 221.5 as / crn2 in order; the cumulative amount of penetration per unit area in each area is sequentially increased to 476.2 times by comparing with polyethylene dihydrazine (PEG) soft jelly as described above , 218.6 times, 41.8 per cent. Obviously, soap corners can promote cheek and transdermal absorption. Among them, 1% soap corners are effective for extracting JL from liquid. And as shown in Figure 10, even if the above prescription (Lin 2) is replaced by 1% oleanolic acid (Oleanolicacid) • Compare the formula containing 1% qi guao acid (# 1) with the 1% saponin extract Prescription ¢ 2) It is found that the transdermal absorption effect of the two is equally good, which proves that the saponin extract is an excellent transdermal absorption accelerator. As shown in Fig. 11 • The reward of diligence performed by covering the gas of the rabbit with the medicine gas was measured after 72 hours. The degree of penetration of the stratum corneum is the most inadequate with a prescription containing 2% glycyrrhizic acid.The cumulative amount of penetration per unit area is 389.8 zig / cro2; and the epidermal layer and the dermal layer are added with 1% chlorophenolic acid and 2 % Glycolic acid is the best square. 2) The best, the cumulative guessing amount per unit surface is 389.8 wg / cm2 ;. As shown in Figure 12, the concentration of the drug in each tissue, whether it contains 2% glycyrrhizic acid, 2% ember and (ACV) coagulant prescription (ttl) * or to which is added 1% zishu fruit acid (tf2) two The concentration of the preparations of the former increased significantly at 72 hours. The cumulative amount of the former was 0.53 ± 0.02 / ig / mi in 72 hours. The cumulative guess of the control group was 0.35 ± 0.03 wg / ml, which was 1.5 times the effective dose. The latter 0.48 ± 0.03 " g / ml is 1.4 times that of the control group. In addition, after measuring the blood concentration of gavage and (ACV) in various organs of rabbits, it was found that the content of 2% carboxylic acid methyl ester cellulose sodium (QC Na) prescription containing 2% glycyrrhizic acid (Oil) in the leaf organs For all kinds of organs up to 6.89 ± 0.38 wg / g only compared with the control group. The paper size is selected by the Chinese National Standard (CNS) f 4 specifications (210x297 mm 1 'door ^ ........... .................................................. ...................... installed ........................ ordered ... ................. Line < Please read the notes on the back before filling the nest page) Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs

A6 B6 經濟部中央棵苹局員工消費合作杜印製 五、發明説明( 處方(料)之含量3·60土0.36 ag/g增加2_2〜1.64倍; 而於聚乙烯二醉(PEG)爲基劑添加2%甘草酸、齊敗果 酸(Oleanolic acid)之處方(#2)於心臟之含量爲各種臟 器之最達8.22士 1.38 wg/g僅比對照組處方W)之含量 3.90士 1.00 M/s增加3.31〜1.39倍;即使於肝臟含量 爲6.42土0.51 /ig/g 僅比對照组之含量2.49土0.85iUg/g 增加4.22〜1.10倍並無造成毒害之虞。如圖13所示, 於人體皮膚含2%甘草酸之2%聪、克和(ACV)凝膠劑,經72 小時皮膚中腮克和濃度較對照組顯著增加6倍。 由於藥物可經皮脂道進行經皮吸收·或製劑中極性較大 之促進劑可能協助藥物經由極性通道產生較大之經皮吸收 故應。本發明利用高壓液態房析法(HPLC)方法求得藥物 促進劑之脂溶性指標,其值列於圈14,、表4。由該表 中藥物及促進劑之溶解皮泰數、脂溶性指標可知,以2 % 腮克和(ACV)、爲基劑添加甘草酸、1 %齊教果酸( Oleanolic acid)所形成之配方有珉好經皮吸收效應’係 基於甘草酸極性較欠而幫助腮克和經由極忮通道(p〇lar pathway)通過,但是齊教果酸極性較低,可«:助胳克和 經由非極性通道〇\/〇rpolarpathway)通過,二者相輔相 成使緦克和凝膝劑產生最大之經皮吸收·效應。 由於聰·克和(ACV)本身之經皮穿透效應很差,而一般 罹患後主要之治療部位在於皮虏之真皮眉c 3前市售品之 腮克和(ACV)软膏不論使用聚乙烯二醇(PEG)、水性冷霜基 劑(Modification aqueous cream )或二曱基岛^(|)路〇) 97公釐)__..一____________________A6 B6 Printed by the consumer cooperation of the Central Bureau of Economic Affairs of the Ministry of Economic Affairs 5. The description of the invention (the content of the prescription (material) 3.60 soil 0.36 ag / g increased 2_2 ~ 1.64 times; and based on polyethylene dihydrate (PEG) The dosage of 2% glycyrrhizic acid and oleanolic acid (# 2) in the heart is up to 8.22 ± 1.38 wg / g in various organs, which is only 3.90 ± 1.00 compared with the control prescription W). M / s increased by 3.31 ~ 1.39 times; even when the liver content was 6.42 ± 0.51 / ig / g, it was only increased by 4.22 ~ 1.10 times compared with the control content of 2.49 ± 0.85iUg / g, and there was no risk of poisoning. As shown in Figure 13, 2% Satoshi, Kewa (ACV) gel containing 2% glycyrrhizic acid in human skin, the cheek and concentration in the skin after 72 hours increased significantly by 6 times compared with the control group. Since the drug can be absorbed through the sebaceous tract transdermally, or the more polar accelerator in the preparation may assist the drug to produce greater transdermal absorption through the polar channel, it should be. The present invention uses the high-pressure liquid chamber analysis method (HPLC) method to obtain the fat solubility index of the drug accelerator, the values of which are listed in circle 14, Table 4. It can be seen from the dissolution of the drugs and accelerators in the table and the fat solubility index, the formula is formed by adding 2% chlorhexidine (ACV), adding glycyrrhizic acid as the base, and 1% Oleanolic acid Youmin good transdermal absorption effect is based on the less polar of glycyrrhizic acid to help cheek and pass through the pole passage (p〇lar pathway), but the polarity of zigzag fruit acid is low, can «: help gram and through non The polar channel (0 // rpolarpathway) is passed, and the two complement each other to maximize the transdermal absorption and effect of Kangke and coagulating agent. Due to the poor percutaneous penetration effect of Satoshi Kehe (ACV) itself, and the main treatment site after the attack is the dermal eyebrow of the skinny c 3 Cheek and (ACV) ointment available before the market regardless of the use of polyethylene Glycol (PEG), Modified aqueous cream (Modification aqueous cream) or Dimethyl Island ^ (|) Road 〇) 97 mm) __ .. 一 ____________________

^ r — ---------—I ......................................................................................裝…..................訂....................線 (犄先閲讀背面之注意事項再填窝本頁)^ r — ---------— I .................................... .................................................. To install ..................... Order ................................. (Read the notes on the back first Refill this page)

、發明説明( ) 基劑•均存在療致不佳之現象。本發明添加中藥之萜類( ! " 丁erpene)、鞣質Cfarmins)、精油(Essential oil)、β顛 S己疏趙(terpene glycoside)等等“藥引于Μ作爲經皮吸· 收促進劑。經各種皮膚進行穿透试驗並由血中濃度征實· 該類製劑所產生之單位面猜穿透累積量比傳统胳克和軚膏 ,约可增加500倍。Π前利用局部投藥之抗病毒藥物尚有 维達賓(Vidarabine)、三氟也峻(Jrifluridine)、破畎咬 (IDU)此等藥物之毒性較低極適用於本發明之局部投藥方 式。本镫明可運用於包括软奮劑、懸浮劑、凝膝劑、溶液 劑、貼劑、噴霧劑等局部投藥製劑,而添加之“藥引子” 經皮吸收促進劑可使用一種中藥“藥引子”,或搭配多種 中藥“藥引子”以增加各種抗病毒藥物之經皮吸收使進效 應。下列以具體實施例説明本發明以不同基劑,加入不同 濃度及不同種類之中藥“藥引子”製成有效之經皮炎收製 劑0 圖式説明: ( X ......................................................................................裝......................訂.....................線.. f請先《讀背面之注意事項再填窝夂頁) |乏:化學结耩式 經濟部中央櫺準局R工消費合作社印«. 圖3 1·寫典2.檢品3·透皮吸收區 4·皮f随5·#口 6.接收槽7·出水口 8·循環水流 9.入求口 10·磁石 9.入水口 10·磁石 腮克和(ACV)水溶轉於蛇皮4始 1··· 0.01%腮1_冬溶參劑 + 0.01%甘草酸(^^ 2...0.01 %腮克和水溶液知 圖4 腮克和(ACV) 劑型於不同種 外穿透试驗 xcyrrhizin) 穿逢 各紙張尺度適用中國Η家樣箏(CNS)T4規格(210X297公釐} ή2. Description of the invention () Bases • There is a phenomenon of poor treatment. "Terpenes", tannin Cfarmins, essential oils, terpene glycoside, etc. are added to the present invention as "medicine is introduced to M as percutaneous absorption and collection promotion Agents. Penetrate tests on various skins and verify the concentration in the blood. The cumulative amount of penetration per unit surface produced by this type of preparation is about 500 times greater than that of traditional gram and pian ointment. Use local administration before Π The antiviral drugs include Vidarabine, Jrifluridine, and IDU. The low toxicity of these drugs is very suitable for the local administration method of the present invention. This stirrup can be used in Including local preparations such as softener, suspending agent, knee coagulant, solution, patch, spray, etc., and the added "medicine primer" percutaneous absorption enhancer can use one kind of Chinese medicine "medicine primer", or mix with a variety of Chinese medicine "Medicine primer" to increase the percutaneous absorption of various antiviral drugs. The following specific examples illustrate the invention using different bases, adding different concentrations and different types of Chinese medicine "medicine primer" to make effective percutaneous inflammation Formulation 0 : (X ............................................... ................................. Pretend .......... ............ Order .................. Line ... f Please first "read the notes on the back and then fill the nest" Page) | Exhausted: The chemical structure of the Ministry of Economic Affairs, Central Bureau of Economic Development, R Industry and Consumer Cooperatives Co., Ltd. «. Figure 3 1 · Writing Code 2. Inspection Product 3. Transdermal Absorption Area 4. Skin f Sui 5 · # 口 6. Reception Groove 7. Water outlet 8. Circulating water flow 9. Inlet mouth 10 • Magnet 9. Water inlet 10 • Magnet gram and (ACV) water dissolves in snakeskin 4 beginning 1. 0.01% gill 1_ winter soluble ginseng + 0.01% glycyrrhizic acid (^^ 2 ... 0.01% cheek and aqueous solution, see Figure 4 Cheek and (ACV) dosage form in different kinds of penetration test xcyrrhizin) CNS) T4 specification (210X297mm)

發明説明()1···裸跋 2.. .80.齡豬皮 3...25曰齡豬皮 凝膠劑型以2 %羧酸甲基酯織維素钠(CMC NA)爲 基劑之2%腮克和凝膝劑会el) 圖5路克和(ACV)於軚膏劑型及凝膠劑剷塑之禮外龠 透试驗 1.. .以2%羧酸甲基酯織维素钻iCMC NA)爲 基劑之2%塍克和娜劑㈣ 2.. .以聚乙烯二酵(PEG)爲基劑聪克 和軟膏劑©intment) 圖β甘草酸i^rlycyrrhizin)含量影春聪*克和(A^V)凝 膠劑劑型之經皮吸收 1.. .以羧酸S&酯織维素韵(CMC NA)爲 基劑+2%甘草酸(如cxcnhizin) 之2%腮克和凝脐劑gel) 2.. .以2%羧酸曱基酯纖雉素钠(CMC ΝΑ)爲 之2%腮克和凝膝劑谷el) 3.. .以2%羧酸甲基酯織维素钠(CMC Μ)爲 基劑之胳克和^^劑*^1) 經濟部中央標準局具工消费合作社印製 (請先閲讀背面之注*事項再填窝各頁) 圖7浞進劑種頹影f腮克和(ACV)凝膝劑劑盤之經皮吸 收 1.. .以2%羧酸甲基酯織雉素纳d-NA)爲 基劑+2 %甘草蘇6丨yarriii^in) 之2 %胳克和凝勝劑“1) 2.. .以羧酸甲基酯織雉素钻d NA)爲Description of the invention (1) Naked posture 2 ... 80-year-old pigskin 3 ... 25-year-old pigskin gel dosage form using 2% carboxymethyl methyl ester oryzanol sodium (CMC NA) as a base Of 2% cheek and knee coagulation el) Figure 5 Luke and (ACV) in the ointment form and gel shoveling shovel outside test 1 .. Weave with 2% carboxylic acid methyl ester Vitamin C (iCMC NA) is 2% of the base and the base agent (2). Using polyethylene diferment (PEG) as the base Cong Ke and ointment © intment) Figure β glycyrrhizic acid i ^ rlycyrrhizin) content Yingchuncong * Kewa (A ^ V) gel dosage form percutaneous absorption 1. Based on carboxylic acid S & ester oryzanol (CMC NA) as a base + 2% glycyrrhizic acid (such as cxcnhizin) 2% cheek and umbilical gel (gel) 2: 2% carboxymethyl carboxylate cellulose ester (CMC ΝΑ) as 2% cheek and knee coagulant el) 3. 2% Carboxylic acid methyl ester oryzanol sodium (CMC Μ) is used as a base and ^^ agent * ^ 1) Printed by the Gonggong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes * on the back before filling the nest (Each page) Figure 7 Percutaneous absorption of Jinjin Fenke and (ACV) knee coagulant tablets 1. .. using 2% carboxylic acid methyl ester Zhizhisu (d-NA) as the base + 2% Licorice Su 6 (yarriii ^ in) of 2% gram Coagulation agent wins "1) .. 2. In carboxylate drill weave prime pheasant d NA) of

本紙張尺度適用中國國家樣準(CNS)甲4规格(210x297公;L :ϋ .......—_| ·| —This paper scale is applicable to China National Standards (CNS) Grade 4 (210x297 g; L: ϋ ....... —_ | · | —

發明説明( A6 B6 烴濟部中央標準局員工消費合作社印製 圖8 基劑+2%齊敗果酸(〇丨咖〇1化 acid)之2 %鹧克和凝膠劑_1) 3··.以2%羧酸甲基酯織维素钠(CMC ΝΑ)爲 基劑 +2%熊果酸(Ursolic acid) 之2 %腮克和凝膠劑&el) 4.. .以2%叛酸甲基酯織維素钠(CMC ΝΑ)爲 基劑+5%桉葉素(Creole) 之2%腮克和凝膝劑〜1) 5.. .以2%叛酸甲基酯織維素钠(CMC NA)爲 基劑+5 %月桂稀(点-myrcene) 之2 %腮克和凝膠劑6el) 6.. .以2%羧酸甲基:酯織維素钠(CMC ΝΑ)爲 基劑 +5;浪烯((+) -.cx 之2 %胳Λ和凝膠劑($el) 7.. .以2%叛酸甲基酯纖維素钠(CMC ΝΑ)爲 ^L^»j +5 % 3^^ ((-) - a-pinene) 8.. .以2%羧酸甲基酯織維素钠(CMC ΝΑ)爲 基劑+2 %甘草次酸(18-召-Glycyrrhetinic acid) ^ 克和凝膝劑(㈣ 9.. .以2%叛酸甲基酯纖維素钠(CMC NA)爲 基劑之2%腮克和凝膠劑如1) 含甘草酸(Slycyrrhizin)之終克fe(ACV)凝膠劑 中添加不同種類或不同含量促_進劑之經皮 吸收 甘草酸(^lycyrrhizin) + 1%齊教 t請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)甲4規格(210X297公釐)Description of the invention (printed by A6 B6 Employee Consumer Cooperative of the Central Standards Bureau of the Ministry of Hydrocarbon Economy 8 base agent + 2% galactic acid (〇 丨 coffee 〇1 chemical acid) 2% part grams and gel agent _1) 3. · 2% carboxymethyl methyl ester oryzanol sodium (CMC ΝΑ) as a base + 2% ursolic acid (Ursolic acid) 2% cheek and gel & el) 4. to 2 % Methyl retinoic acid sodium ester oryzanol (CMC ΝΑ) as a base + 5% eucalyptus (Creole) 2% cheek and knee coagulant ~ 1) 5. .. 2% methyl retinoic acid Oryzanol Sodium (CMC NA) as a base + 5% laurel dilute (point-myrcene) 2% cheek and gel 6el) 6. .. 2% carboxylic acid methyl ester: ester oryzanol sodium ( CMC ΝΑ) as a base +5; langene ((+)-. Cx of 2% Λ and gelling agent ($ el) 7... 2% sodium methyl cellulose carboxylate (CMC ΝΑ) Is ^ L ^ »j +5% 3 ^^ ((-)-a-pinene) 8. .. using 2% carboxylic acid methyl ester oryzanol sodium (CMC ΝΑ) as a base + 2% glycyrrhetinic acid (18- 召 -Glycyrrhetinic acid) ^ Gram and knee coagulant (㈣ 9. .. 2% cheek and gel based on 2% sodium methyl cellulose carboxylate (CMC NA) as the base, 1) Transdermal glycyrrhizic acid (Slycyrrhizin) containing the final gram fe (ACV) gel with different kinds or different contents Close glycyrrhizin (^ lycyrrhizin) + 1% QI teach t Please read the back of the precautions to fill out this page) This paper scale applicable Chinese National Standard (CNS) A 4 size (210X297 mm)

五 經濟部中夬標準局員工消費合作社印製 『㈣”’正 充 、發明説明( ) 策酸(〇1钟nolic acid)之胳克 和凝膝劍(令el) 2.. .2% 甘草酸Oflycyrrhizin) + 2%聪克 和之次乙基乙二醉(EG)懸浮劑 3.. .2% 甘草酸窃ycyrrhizin) +20%— 甲 基亞(DMS0)之2¾胳克和凝膝劑 命1), 4· · · 2 %甘草酸蜂ycyrrh izin)之2 %胳克 和贿劑右el) 5.. .2% 甘草酸(i^ycyr,r‘hizin) + 1%熊果 酸(Ursolic acid)之2% 聪'^*^ 膠劑(^1) 6.. .2% 甘萆酸(^lycyrrhizin) + 旅烯 ((+) - 〇( jpinene)之2 % -、聪,克和凝 膠劑(^el) 圖'9含甘萆酸屮ycyrrhizin)之胳克和(Ο)凝膠劑 ,中添加不同含量息角Gleditsia sinensis Um.)促進劑之經皮吸收 1··.1% 皂角(《leditsia sinensis haia.) + 甘草酸(^lycyrrhizin)之2% 涊克和凝膠劑(Gel) 2·.·2% 泉角 6leditsia sinensis |am·) + 甘草酸 Glycyrrhizin)之2% 悠克和凝膠劑gel) 3···2%腮克和凝勝劑(辞1) 圖10促進劑影響腮克和(ACV)凝膠费1矣經皮吸收皂角 .....................................................................................裝......................訂.....................線 (請先閲讀背面之注意事項再填窝本頁) 本紙張尺度適用中國國家樣準(CNS)甲4规格(210χ297公*){ 丨士fc:Fifth Ministry of Economic Affairs, China National Bureau of Standards and Staff, Employee Consumer Cooperative printed the "㈣" 'full charge, description of invention () Zac acid (〇1 钟 nolic acid) 克克 and coagulated knee sword (令 el) 2. 2% glycyrrhizic acid Oflycyrrhizin) + 2% Cong Ke and the next Ethylene Glycol (EG) suspension agent ... 2% glycyrrhizin ycyrrhizin) + 20%-2¾ g of Methylene (DMS0) and knee coagulant 1), 4 ·· 2% glycyrrhizic acid bee ycyrrh izin) 2% gram and bribe (right el) 5. 2% glycyrrhizic acid (i ^ ycyr, r'hizin) + 1% ursolic acid ( Ursolic acid) 2% Satoshi '^ * ^ Adhesive (^ 1) 6. 2% glycyric acid (^ lycyrrhizin) + triprene ((+)-〇 (jpinene) 2%-, Satoshi, g And gel (^ el) Figure '9 containing gluconate (cycyrrhizin) gram and (Ο) gel, with different content of Gleditsia sinensis Um.) Accelerator percutaneous absorption 1. 1% saponin ("leditsia sinensis haia.) + 2% of glycyrrhizic acid (^ lycyrrhizin) 2% chaohe and gel (Gel) 2 ·. · 2% quanjiao 6leditsia sinensis | am ·) + glycyrrhizin Glycyrrhizin) 2% Youke and gel) 3 ··· 2% cheek and gelling agent (Glossary 1) Figure 10 Accelerator affects cheek and (ACV) gel fee 1 Soap absorption ............................................. ................................ Pretend .............. ........... Order ..................... line (please read the precautions on the back before filling this page) This paper The scale is applicable to China National Standards (CNS) Grade 4 (210 × 297 g *) {丨 士 fc:

L、發明説明( ) A6 B6 (§leditsia sinensis lam.)抽取 1··.1% 齊敗果酸(〇leanoiic acid) +2% 甘草酸(含17〇71^11丨2丨1>1)之2%聪>克 和凝膠劑㈣ 2.. .息角(j^leditsia sinensis lam.) 之抽取+2%甘草酸(^lycyrrhizin) 之2¾腮克和凝膝劑gel) 3.. .2. 甘萆酸(^lycyrrhizin) +0.332% 腮克和凝膝劑gel) 4.··2% 甘草酸(j^lycyrrhizin)之2% 胳克 和凝膝劑㈣ 圖Π貼劑於兔耳各皮層經貼片72 hr後藥量分佈情形, 栝號之數字表示與其比較之處方 1.. .以2%羧酸甲基酯織雒素钠(CMC NA)爲 基劑 +2% 甘莩酸(j^lycyrrhizin) 之之允腮克和凝膠‘…二比) 2.. .以2%羧酸曱基酯織雉素钠(CMQNA)爲 基劑+2%齊敗策酸jQleanoiic acid)之2%胳克和凝'膠劑(n=6) 3…2%甘革酸$lycyrThizin)之2%胳克 和凝膝劑(n=6) 4.. .以2%羧酸曱基酯織维素鈉(CMC ΝΑ)爲 基劑之2%胳克和凝縢劑(η=13) 圖12貼劑於兔耳各皮及經貼片72 hr·後#中濃度^ 栝號之數字表示與其比較之處方 1.. .以2%羧酸曱基酯纖維素钠(CMC NA)爲 本紙張尺度逋用中國0家標準(CNS)甲<4规格(210x297公釐)L. Description of the invention () A6 B6 (§leditsia sinensis lam.) Extract 1 · .1% oleic acid (〇leanoiic acid) + 2% glycyrrhizic acid (containing 17〇71 ^ 11 丨 2 丨 1> 1) Of 2% Satoshi > g and gel (2). Extraction of angle of interest (j ^ leditsia sinensis lam.) + 2% of glycyrrhizic acid (^ lycyrrhizin) 2¾ g and knee gel (gel) 3. .2. Glycolic acid (^ lycyrrhizin) + 0.332% cheek and knee coagulant gel) 4.2% 2% glycyrrhizic acid (j ^ lycyrrhizin) 2% gram and knee coagulant (iv) Figure Π patch on rabbit The distribution of the dose of the cortex of the ear after 72 hr, the number of the Toku No. indicates the comparison with it .... 2% carboxymethyl sodium carboxylate (CMC NA) as the base agent + 2% Gan掩 酸 (j ^ lycyrrhizin) 's permissible gel and gel' ... two ratios) 2. Using 2% carboxylic acid methyl ester crocodile sodium (CMQNA) as a base + 2% chloroacetate jQleanoiic acid) of 2% gram and gelatin (n = 6) 3 ... 2% glycerine $ lycyrThizin) of 2% gram and coagulant (n = 6) 4. .. with 2% carboxylic acid Methyl ester oryzanol sodium (CMC ΝΑ) is 2% of the base and coagulant (η = 13). Figure 12 The patch is applied to each skin of the rabbit ear and the patch is 72 hr · post #medium concentration ^ 栝The number of the number indicates its comparison Party 1 .. 2% Yue carboxylic ester sodium carboxymethylcellulose (CMC NA) of the present paper Bu scale with 0 China Standards (CNS) A <. 4 size (210x297 mm)

五、發明説明( ) A6 B6 基劑 +2% 甘草酸(ftycyrrhizin) 之2 %胳克和凝膝劑(n=6) 2.. ·2%甘草酸仓lycyrrhizin) +1%齊敗策 酸(Gleanolic acid)之胳克 和凝膠劑(n=3) 3.. .2. 甘草酸(Olycyrrhizin)之2% 胳克 和凝揮劑(n=3) 4.. .以2%羧酸甲基酯戚雉素纳CMC ΝΑ)爲 基劑之2 %胳克和凝膝劑(η=6) 圖.13貼劑於兔耳各皮滑經貼片72 hr後各藏氣、組織 濃度•括號之數字表示與其比較之處方 1.. .以2%致酸甲基酯纖維素钠(CMC NA)爲 基劑 +2% 甘草酸(Glycyrrhizin) 之膝克和凝膠劑(n=6) 2· · · 2 % 甘草酸(¾} ycyrrh iziη) +1 % 齊敗策 酸(〇丨6311〇1卜3(:丨〇1)之2%胳克 和凝膠劍(η=3) 3·..2%甘草酸谷lycyrrhizin)之2%胳克 和凝勝劑(ηθ) 4·..以2%羧酸甲基酿缄旅素铂(cmc ΝΑ)爲 基劑之2 %膝克和凝勝劑(η=6) 圖14促進劑之脂祕指標 1·..甘草疏 2...甘莩次酸 3.··蒎烯 4.··召-月桂烯 甲4規格(210x297公釐]… ιΛ {請先閲讀背面之注意事項再填窝本頁> ..裝 訂 經濟部中夬標準局員工消費合作钍印奴 3 A6 B6 經濟部t央標準局員工消费合作社印製 五、發明説明( ) 實施例1 軟赍劑(Ointment)劑型之調製 捋5%重量百分率之想克和(ACV)溶於已加熱至75t: 之5%重量百分率次乙基乙二醉(EG)溶液中,於另一容器 中將45%重量百分车之聚乙烯二酵(PEG) 400與45%重量 百分车之聚乙烯二酵_混和加熱至75t: ·再均勻混合 加入已製镩之胳克和混合涫液,於25^中急速冷卻攪拌 而成。 實施例2〜5 含促進劑软膏劑型之調製 · 比照賞施例1之製備方法分別加入1 %重量百分率之 泉角(Gleditsia sinensis Lam.)抽取液,或1%、2%、 5%重量I分率之甘革酸(Giycyrrhizin),於75t次6基 乙二酵(EG)溶波。 實施例6〜8 調製含甘油之第一類塑凝膠剩«}elJ 劑型 稱取2¾重量百分率之胳克和(ACV)與2%、4%、6% 重量百分率之致酸甲基酯纖维素钠(CMC Na)溶於水中*於 另一容器稱取50%重量百分率之甘油(GlyCeriu) ·再均勻 混入已製佛之鹧克和混合液,添加適量水分至2〇 mi。 實施例9〜10 調製含甘草酸第一類型凝膠劑(Ge 1) 劑噔之調製 尺度逋用中國國ϋ準(CNS)甲4规格(U10 X 297公;f) : ~ ::涵 {請先閲讀背面之注意事项再填寫本頁) .裝 .訂 .線 Α6 Β6 2377/ί 五、發明説明( ) 比照實施例6之製餚方法*稱取2%重量盲分率之致 酸甲基勘繡維素钠(CMC Na)分別捋2%、5%重量百分率 之甘草斑(Glycyrrhizin)溶於水中,製成含有甘草酸之第 一類型凝膝劑(Gel)劑。 賞施例11 調製含次乙基乙二酵之第二類型凝膝剩 (Gel)劑型 稱取2%重量百分率之胳克和(ACV)溶於20%重量百 分率之次乙基乙二酵(EG)中,於另一容器稱取2%重量百 分牟之羧酸甲基酯織維素钠(CMC Na)溶於水中,苒均勻>孔 入已製镩之胳克和泯合液,添加適量水分至20 ml。 實施例12〜19 含促進劑之第二類型凝膠劑(Gel)劑 型之調製 比照實施例11之製餚方法,分別稱取5¾重量百分率 含於蜗萵花、擴莩根、薄荷、紫蘇葉、欠棗、胡椒、厚朴 、辛夷、白豆蔻、莪私、1、香附于、番紅花之蒎烯[(ls )-㈠-or-pinene] 重量百分牟含於熊果·葉、山策致 、大棗之熊策酸(Ursolic acid) ; 2%重量百分率含於甘 萆之甘萆次酸(18-e-Glycyrrhetinic acid)或2Y重量 百分牟之甘革酸((Uycyrrh i z i η) ; 2 % ί量备分车含'於在 連翹、山苽萸、丁香、欠棗之齊氣策酸(Oleanolic acid) ;5 %重量百分率含於忽布、白豆蔻及I之月栓稀( mvrcene) ;5%重量百分率含於茴香·、肉豆蔻之蒎烯[卜) 本紙張尺度ΐϊ閃國家櫺準(CNS)甲4規ϋ210><297公藿) ------ ίί ., { .....................................................................................裝......................訂.....................線 {請先閲讀背面之注意事項再填窝本頁) 經濟部中央標準局Λ工消费合作社印製 A6 B6 經濟部中央標準局R工消费合作社印製 五、發明説明( ) -α-Pinene] ; 5%重量百分率含於辛夷、鬱金及番紅花之 桉葉素(Cineole)溶於次乙基乙二醇(EG)。 實施例20 調製僅含次乙基乙二醉(EG)爲基劑第三 類塑之凝膠劑(Gel)劑塑 稱取0.247%重量百分率之腮克和(ACV)溶於5%重 量苜分率次乙基乙二醇⑽),再均勻混入2%重量百分率 之甘莩酸(Glycyrrhizin)以適量水份於研体中3L勻》於 3,000 rpm下離心30分鐘取上清液。 賞施例21調製不同主成份第三類型之凝膠劑(Gel) • 劑型 比照賞施例20之製備方法,稱取0.683%重量百分率 之胳克和(ACV)溶於次乙基乙二醇(EG),再均勻混入1 % 重量百分率之甘草酸(Glycyrrhizin)汛勻•於3,000 rpm 下離心30分鐘取上清液。 贲施例22調製不同主成份第三類型之凝膠劑(Gel) 劑型 比照實施例20之製備方法,辞取0.852%重量百分牟 之烬克和(ACV)溶於次乙基乙二醉(EG) *再混入3%重t 百分率之甘莩酸(Glycyrrhizin)泯勻,於3,000 rpm下離 心30分鐘取上清液。 , f請先《讀背面之注意事項再填窝本頁) { .裝 .訂 .線V. Description of the invention () A6 B6 base + 2% glycyrrhizic acid (ftycyrrhizin) 2% gram and knee coagulant (n = 6) 2 .. 2% glycyrrhizic acid silo lycyrrhizin) + 1% valeric acid (Gleanolic acid) gram and gel (n = 3) 3 .. 2. 2% glycyrrhizic acid (Olycyrrhizin) 2% gram and coagulant (n = 3) 4 .. with 2% carboxylic acid Methyl ester pheasant sodium CMC ΝΑ) is the base of 2% gram and knee coagulant (η = 6). Fig. 13 Gas and tissue concentration of the patch after sliding on the skin of the rabbit ear for 72 hr • The numbers in parentheses indicate where they are compared. 1. .. Using 2% sodium carboxylate methyl cellulose (CMC NA) as the base + 2% glycyrrhizic acid (Glycyrrhizin), Ginkgo and gel (n = 6) ) 2 · 2% glycyrrhizic acid (¾) ycyrrh iziη) + 1% chloropic acid (〇 丨 6311〇3 Bu 3 (: 丨 〇1) 2% gram and gel sword (η = 3) 3 .. 2% glycyrrhizin lycyrrhizin) 2% gram and coagulant (ηθ) 4 · .. 2% knee with 2% carboxylic acid methyl brewerine platinum (cmc ΝΑ) as the base Kehe coagulation agent (η = 6) Figure 14: Fat secretion index of accelerator 1 · .. licorice sparse 2 ... Glycolic acid 3. ·· pinene 4 .. · zhao-myrcene A 4 specifications ( 210x297mm]… ιΛ {Please read the notes on the back first Item refill page> .. Binding Ministry of Economic Affairs Zhongshang Standards Bureau Employee Consumption Cooperation Th Indo 3 A6 B6 Printed by the Employee Consumer Cooperative of the Central Standards Bureau of the Ministry of Economy V. Description of Invention () Example 1 Soft Soap ( Ointment) The dosage form is prepared by dissolving 5% by weight and ACV in a solution of 5% by weight of ethyl ethanedihydroxide (EG) which has been heated to 75t: 45% by weight in another container PEG 400 and 45% by weight PEG of yeast _ mixed and heated to 75t: · Then mix evenly and add the prepared gram and mixed liquid, in 25 ^ It is made by rapid cooling and stirring. Examples 2 to 5 Preparation of the ointment containing accelerators. According to the preparation method of Example 1, add 1% by weight of the spring liquid (Gleditsia sinensis Lam.) Extract, or 1%, 2 %, 5% by weight of glycerin acid (Giycyrrhizin), dissolve at 75t times 6-glyoxal (EG). Examples 6 ~ 8 Preparation of the first type of plastic gel containing glycerol «} elJ dosage form Weigh 2¾ weight percent of the gram sum (ACV) and 2%, 4%, 6% weight percent of the resulting acid methyl ester cellulose sodium (CMC Na) * In water in a separate container was weighed 50% glycerol by weight percent of (GlyCeriu) · g and then the mixture mixed uniformly partridge has made Buddha, a suitable amount of water to 2〇 mi. Examples 9 ~ 10 The modulation standard of the first type of gel agent containing glycyrrhizic acid (Ge 1) was prepared using the Chinese National Standard (CNS) A 4 specifications (U10 X 297 g; f): ~ :: Han { Please read the precautions on the back before filling in this page). Binding. Binding. Line Α6 Β6 2377 / ί 5. Description of the invention () According to the recipe preparation method of Example 6 * Weigh the 2% by weight to give acid CMC Na is used to dissolve 2% and 5% by weight of Glycyrrhizin (Glycyrrhizin) in water to prepare the first type of Glycyrrhizin (Gel) agent containing glycyrrhizic acid. Example 11 Preparation of the second type of Glycogen Residue (Gel) dosage form containing ethylenediethylenzyme Weigh 2% by weight of gram and (ACV) dissolved in 20% by weight of ethylenediethylenzyme ( EG), in a separate container, weigh 2% by weight of carboxylic acid methyl ester sodium carboxylate sodium (CMC Na) dissolved in water, 苒 evenly> hole into the prepared gram and the mixture , Add appropriate amount of water to 20 ml. Examples 12 to 19 The preparation of the second type of gel (Gel) containing the accelerator was prepared according to the preparation method of Example 11, and 55% by weight were weighed and contained in the snail lettuce flower, expanded root, mint and perilla leaves. , Owe date, pepper, Magnolia officinalis, Xinyi, white cardamom, Curcuma, 1, fragrant, saffron pinene [(ls) -㈠-or-pinene] The weight percentage is contained in bearberry leaves, Ursolic acid of Shancezhi and Jujube; 2% by weight contained in glycerol acid (18-e-Glycyrrhetinic acid) or 2Y weight percent glycerol acid ((Uycyrrh izi η); 2% of the amount of spare parts is contained in Oleanolic acid in Forsythia suspensa, Cornelian cherries, cloves, and jujubes; 5% by weight is contained in Kubu, White Cardamom, and I suppository Dilute (mvrcene); 5% by weight contained in fennel, nutmeg [pine] [Bu] The paper size is ?? National Standards (CNS) A 4 regulations ϋ210 > < 297 public hops) ------ ίί., {.............................................. ................................. Pretend .......... ............ order .................. line {please read the back first Please fill in this page again) A6 B6 printed by the Central Standards Bureau of the Ministry of Economic Affairs and Industry and Consumer Cooperatives. B6 Printed by the R and Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economy V. Description of the invention () -α-Pinene]; 5% by weight Cineole of Xinyi, turmeric and saffron is dissolved in ethylene glycol (EG). Example 20 Preparation of the third type of plastic gel (Gel) containing only ethyl ethanedithione (EG) as the base plastic Weigh 0.247% by weight of the cheek and (ACV) dissolved in 5% by weight of alfalfa Ethylene glycol fraction ⑽), and then evenly mix 2% by weight of glycyrrhizin (Glycyrrhizin) with an appropriate amount of water in the mortar 3L, centrifuge at 3,000 rpm for 30 minutes to take the supernatant. Example 21: Prepare a third type of gel (Gel) with different main ingredients. The dosage form is the same as the preparation method of Example 20. Weigh 0.683% by weight of gram and (ACV) in ethyl ethyl glycol. (EG), then mix evenly with 1% by weight of glycyrrhizic acid (Glycyrrhizin). • Centrifuge at 3,000 rpm for 30 minutes to take the supernatant. Benshi Example 22 prepares the third type of gel (Gel) with different main ingredients. The dosage form is the same as the preparation method of Example 20, and it quits 0.852% by weight of ash and (ACV) and dissolves in ethyl ethyl dihydroxide. (EG) * Add 3% weight t percentage of glycyrrhizin (Glycyrrhizin) to homogenize, centrifuge at 3,000 rpm for 30 minutes to take supernatant. , F Please first "Read the notes on the back and fill the nest page" {. 装. 定. 线

A6 B6 經濟部t央標準局员工消费合作杜印製 五、發明説明( ) 實施例23 調製含兩種促進劑之第三類型凝膠劑 (Gel)劑型 比照實施例20之製佛方法,分別稱取0.305%重量百 分率之聪、克和(ACV)、重量I分率之甘萆酸、5%重量 百分牟之大風子之油酸(Oleic acid)於研砵中混勻,以 3,000 ι Ριά 丁離心30分鐘取上清液。 賞施例24 調製含兩種促進劑之第三類型凝联 劑(Gel)劑堃 比照實施例20之製傷方法,分別稱取0.648%重量百 分率之您克和(ACV)、2 %重量百分率之甘草酸、2 %重量 百分率之甘草次酸(18·^-Glycyrrhetinic acid)於研蛛 中混勻,以3,000 rpm下離心30分鏟取上清液。 實施例25 調製僅含次乙基乙二醇(EG)爲基劑 第三類型之凝膠劑(Gei)劑型 稱取1 %重量百分率之胳克和(ACV)溶於5 %重量百 分率次乙基乙二醉(EG),再均勻混入2 %重量百分率之甘 草酸(〇^>『.「11丨*2丨/1)以適量水汾於研砵中混勻,於3,000 rpin下離心30分鐘取上清波。 賞施㈤26〜32 調製含不同足進劑以次乙基乙二醉爲 基劑之凝膠劑(Gel)劑型 f請先《讀背面之注意事項再填寫木頁) .裝 •訂 .線 本紙張尺度適用中a a家標準(CNS)甲4规格(210x297公釐) .· J --丨、 A6 B6 熳濟部中央楳寧局貝工消费合作社印製 五、發明説明( ) 比照實施例25之製備方法,稱取聪·克和(ACV)溶於次 乙基乙二醉(EG) ·再分別於甘萆酸(Glycyrrhizin)中添加 1%、2%重量百分率之齊敗策酸(Oleanolic acid) 重量百分率之渡烯[(+)-a-Pinene] ; 、2%重量百分 率之鬼角(Gleditsia sinensis Lam.) ; 20%重董百分率 之二甲基逛©^)丨111杜1奴181111>〇){丨(1);1%重量百分率之熊 策酸(Ursoic acid)溶於次乙基乙二踔ffiG)中•最後加入 適量水份^^研蛛中浪合均勻。 實施例33 懸浮劑(Suspension)劑型之辑製 稱取2 %重量百分率之胳克和(ACV)溶淤98 %重量百 分率之次乙基乙二醇(EG)中於研砵中混合均勻。 賞施例34 調製含不同促進劑之懸浮劑 (Suspension)劑型 比照賞施例33之製備方法,於50%重量百分率次乙 基乙二醇(EG)中,均勻混入2%重量百分率之甘莩之甘萆 酸((iiycyrrhizin) ° 實施例35 網製含不同促進劑之懸浮劑 (Suspension)劑型 比照實施例33之製镛方法,於96%重量百分率次乙 基乙二酵(EG)中,均旬混入2%重量百分率之甘萆之甘萆 (請先《讀背面之注意事項再壜窝本頁) -裝 .訂 -線一 A6 B6 經濟部中央標準局貝工消费合作社印製 五、發明説明() 甘草次酸(18-e-Glycyrrhetinic acid)。 賁施例36· 調&含不同促進剧之懸浮劑 (Suspension)劑型 比照實施例33之製備方法*稱取5%重量百分率之聪 克和(ACV)溶於94%重量百分率次乙基乙二醇(EG)中, 均勻混入1%重量百分率之皂角((Heditsia sinensis Lam.)。 實施例37 溶波劑(Solution)剩型之調製 稱取0.1 %重量百分率之腿克和(ACV)溶於適量水中, 以超音波振盪器使其完全溶解混合。 實施例38 調製含不同促進劑之溶疚劑 (Solution)劑型 比照實施例37之製備方法,於腮克和(acv)溶液劑中,均勻浪入0.1%重量¥分率之甘草酸((}1穴:^外4111)〇 實施例32 調製含不同促進劑之溶波劑 (Solution)劑頊 比照實施例37之製佛方法,稱取〇·〇5%重量百分率 之路克和(ACV)溶於適量水中。 {請先閲讀背面之注意事項再填窝本頁) .裝 .訂 .線 本紙張尺度適用t國國家標準(CNS)甲4規格(210X297公釐 缓濟部中央標準局貝工消费合作社印製 A6 B6 ----------、 五、發明説明( ) 實施例40 調製含不同促進劑之溶液劑 (Solution)劑型 比照實施例39之製佛方法,於胳克和(ACV)溶洗劑中 •均勻汛入0.005%重量苢分率之皂角(Gleditsia sinensis Lam.)抽出液。 實施例41 比照實旄例1〜37之软青劑、凝琢劑、懸浮劑、 溶液劑製#方法’以维達賓(Vidarabine)、三氣腹咬 (Trifiuridine)抗病毒藥^代替腮克和(ACV)製備成 經皮吸收劑型。 實施例42 比照實施例1〜37製備經皮吸收剩塑之方法·以單袼 類配疏趙、三萜類配疏體、三萜類皂苷、鞣質、精油,代 替其中之甘草中所含之甘草酸(Glycyrrhizin)、甘草次酸 (18-冷-Glycyrrhetinic acid);連起、]麥、大棄山菜 萸中藥之齊敗策酸(〇iean〇nc acid);茴香、肉豆蔻之蒎 婦((+)-a-pinene);皂角(Gleditsia sinensis Lara.); 熊果葉、山策萸、大棗之熊栗酸(Ursoic scicl)。 、請先J?tl背面之:¾.%事If再壤窝本頁) .裝 -訂A6 B6 Printed by the Ministry of Economic Affairs, Central Bureau of Standards, and Employee Consumer Cooperation V. Description of the invention () Example 23 The preparation of the third type of gel (Gel) dosage form containing two accelerators is compared with the Buddha preparation method of Example 20, respectively Weigh 0.305% by weight of Satoshi, Kehe (ACV), 1% by weight of amarine acid, 5% by weight of oleic acid (Oleic acid) and mix in a research pot, taking 3,000 ι Take the supernatant by centrifuging for 30 minutes. Example 24: Prepare a third type of coagulant (Gel) containing two accelerators. Compare with the wound-making method of Example 20. Weigh 0.648% by weight of your grams (ACV) and 2% by weight. Glycyrrhizic acid and 2% by weight of glycyrrhetinic acid (18 · ^ -Glycyrrhetinic acid) were mixed in the grind spider and centrifuged at 3,000 rpm for 30 minutes to shovel the supernatant. Example 25 Preparation of the third type of gel (Gei) containing only ethylidene glycol (EG) as the base. Weigh 1% by weight of the gram and (ACV) dissolved in 5% by weight of sub-B Ethylene Glycolate (EG), and then mix evenly with 2% by weight of glycyrrhizic acid (〇 ^ > "." 11 丨 * 2 丨 / 1), mix it with appropriate amount of water in Yanfen, and centrifuge at 3,000 rpin Take the clear wave in 30 minutes. Appreciation (26 ~ 32) Prepare a gel (Gel) dosage form with different footing agents based on ethyl ethyl diazoxide. Please read "Precautions on the back side and fill in the wooden page" first .Binding and binding. The size of the line paper is applicable to the aa family standard (CNS) A4 specification (210x297 mm). · J-丨, A6 B6 Printed by Beigong Consumer Cooperative of Central Jining Bureau, Ministry of Economic Affairs Description () According to the preparation method of Example 25, weigh Satoshi · Kehe (ACV) dissolved in ethyl ethanedihydroxide (EG) · Add 1% and 2% by weight to Glycyrrhizin respectively Oleanolic acid (Oleanolic acid) weight percentage [(+)-a-Pinene];, 2% weight percentage (Gleditsia sinensis Lam.); 20% weight percentage of dimethyl ^) 丨 111 Du 1 slave 181111> 〇) (丨 (1); 1% by weight of Ursoic acid (Ursoic acid) dissolved in ethylidene ethylene oxide) Finally add the appropriate amount of water ^^ Scientific spider The middle waves are evenly combined. Example 33 Preparation of Suspension Formulation Weigh 2% by weight of gram and (ACV) dissolved silt and 98% by weight of sub-ethyl ethylene glycol (EG) in the research pottery Mix them evenly. Example 34 Prepare the Suspension containing different accelerators according to the preparation method of Example 33. Mix 50% by weight of ethylene glycol (EG) in a uniform amount of 2% by weight. Example: (iiiicyrrhizin) ° Example 35: Suspension formulation with different accelerators prepared by netting. According to the method of preparation of example 33 in Example 33, at a weight percentage of 96% by weight of ethylene glycol (EG ), Mixed with 2% by weight of yam yam (please read the precautions on the back and then this page) -install.book-line A6 B6 Printed by Beigong Consumer Cooperatives, Central Bureau of Standards, Ministry of Economic Affairs System V. Description of the invention () Glycyrrhetinic acid (18-e-Glycyrrhetinic acid). Ben Shi Example 36 · Tune & contains different promotion dramas Suspension (Suspension) dosage form according to the preparation method of Example 33 * Weigh 5% by weight of Zongke and (ACV) dissolved in 94% by weight of ethylene glycol (EG), evenly mixed into 1% by weight The soap angle ((Heditsia sinensis Lam.). Example 37 Preparation of the remaining type of the solution (Solution) Weigh 0.1% by weight of leg grams and (ACV) dissolved in an appropriate amount of water, and completely dissolve and mix with an ultrasonic oscillator. Example 38 The preparation of a solution containing different accelerators (Solution) is prepared according to the preparation method of Example 37, and the glycyrrhizic acid ((}) is evenly added to the 0.1% by weight ¥ fraction in the cheek and (acv) solution. 1 point: ^ outer 4111) 〇 Example 32 The preparation of a solution containing different accelerators (Solution) agent Xu according to the method of making Buddha in Example 37, weighed 0.05% by weight Luke sum (ACV) Dissolve in an appropriate amount of water. {Please read the precautions on the back before filling the nest page). Binding. Binding. The size of the line paper is applicable to the National Standard (CNS) A 4 specifications (210X297mm Central Standards Bureau of the Ministry of Economic Relief) Printed by the industrial and consumer cooperatives A6 B6 -------, V. Description of the invention () Example 40 The formulation of a solution containing different accelerators (Solution) is compared with the Buddha-making method in Example 39. In the Kehe (ACV) lotion, evenly add 0.005% by weight of the saponin (Gleditsia sinensis Lam.) To extract the liquid. Example 41 Comparatively apply the soft greening agent, coagulating agent of Examples 1 to 37, Suspension agent, solution preparation method #Replace Vibrabine and Trifiuridine antiviral drugs ^ (ACV) Prepared as a transdermal absorption dosage form. Example 42 The method for preparing percutaneous absorption residual plastic according to Examples 1 to 37. Use single shells with sparse zhao, triterpenes with sparse bodies, triterpenoid saponins, tannins , Essential oil, instead of glycyrrhizic acid (Glycyrrhizin) and glycyrrhetinic acid (18-cold-Glycyrrhetinic acid) contained in the licorice; lianqi,] wheat, big abandoned mountain cornflower traditional Chinese medicine qi failure policy acid); fennel, nutmeg pinto ((+)-a-pinene); saponin (Gleditsia sinensis Lara.); bearberry leaves, mountain cornel, jujube ursolic acid (Ursoic scicl)., please First of all, the back of J? Tl: ¾.% If Then again this page). Binding-binding

本紙張尺度逋用中a國家樣準(CNS)甲4規格(210X297公*) A6 B6 五、發明説明( ) 實施例43 於雄外經皮穿透试驗裝置之上、下二層間炎著人趙皮 膚、孕婦分说時取下之羊暖,或蛇全皮、25日、80曰齡 荷蘭豬(guinea pig)之皮肩以及蜂性7至9遇欠之ICR 或Balb/C種母裸鼠(Nude Mice)之皮膚皮作爲试驗皮膚 (暖)材料,以研究抗病毒藥物與中作爲參透障壁,利用 金屬固定失加以固定。以各種經皮吸收劑型進行72小時 之穿透试驗,而於各時閒由取樣口(samp丨ing port) 柚取200 /i 1之氣化钠溶液樣品,經髙壓灰態層析法( HPLC)分析主成份之含量,依校正曲線換算出藥品穿透量 ,判斷製劑之釋出程度。 實施例44 絝經皮吸收劑型*蓋於家兔耳朵,經72小時後測定 該耳朵各層皮廣之胳克和(ACV)濃度。經高壓波態層析法 (HPLC)分析血液及各種臟器之胳克和(ACV)濃度以評估含 .促進劑劑漤之體内穿透及各器官分佈之情形。 <請先閲讀背面之注意事項再填窝本頁) .裝 .訂 .線 經濟部中央標準局霣工消费合作社印*. 本紙張尺度適用中國國家搮準(CNS>甲4規格(210X297公釐) ί;1. 2j9 μ] /〇 2故"1益 § 表、2-l作爲經皮吸敗促進劑中藥藥材 (Arteoisiae Capillaris Herba): (essential oi 1) ; capi 11 in、capi 1 lene、capi 1 lone、capi 1 larin、 Nw'capi 1 lene、capi 1 lanol (Qirysantheium): 精油(essential oil);㈠-tx-Bisabolol、〇(-Farnesene、Matricin Matricarin、Chanazulene、 ie (Cinae Flos) : 衝由(essential oil):㈠-〇c-Pipene、Terpinene、Terpineol、 Carvacrol、a-Thujone、㈠-Camphor、 (Saussureae Radix): • Γ ----:-----裝| (請先閱讀背面之注$項再行繪製) 香 精油(essential oi 1) ; Aplotaxene、Costic acid、Costunol ide、 Costus lactone' Dehydrocostus lactone' Dihydrocostus lac1 Phellandrene、α-Ionone、/3-Ionone、σ-Costol、Camph^ie、 actone 擷 草 根 (Valerianae Radix): jHHi (essential oil) ; (+)B«niylisoval«'ate ^ Bornylacetate' Kessane ' ㈠-Campehne、(+ -)-Liaonene、ot-Twpineol、α-Kessylaicdiioi、 cx-fesylalcdiol acetate、Kessanol、Kessoglycol、Valeranwie、 Fauronyl acetate ^ Cryptofauronol' Kanokonyl acetate' Linalool、/3-Pi_e、Kandwml、a-Pinoie 订 薄 荷 (Maithae Herba): m (essential oil) :、(-)-ifenthol、Acetyllnenthol、㈠-Moithone、 ㈠-Liaoiene、(+)-tethol Puleg(»ie、Piperitoie、Is«Baitiione、 Cdnphene、3-0ctanol、γ -Hexenyi、Penylacetate、a-Pinene、This paper uses the Chinese National Standard (CNS) A4 specifications (210X297 g *) A6 B6 5. Description of the invention () Example 43 Inflammation on the upper and lower two layers of the male external percutaneous penetration test device People's skin, sheep warmed by pregnant women, or whole skin of snakes, skin shoulders of Guinea pigs on the 25th and 80th, and ICR or Balb / C breeds owed by bees of 7-9 The skin of nude mice (Nude Mice) is used as a test skin (warm) material to study antiviral drugs and medicaments as a barrier to penetration, and is fixed by metal fixation. A 72-hour penetration test was carried out with various percutaneous absorption dosage forms, and a 200 / i 1 sample of vaporized sodium solution was taken from the sampling port at each time, and subjected to high pressure gray state chromatography (HPLC) Analyze the content of the main ingredients, convert the drug penetration according to the calibration curve, and judge the release degree of the preparation. Example 44 A percutaneous transdermal absorption dosage form was applied to the ears of rabbits, and the concentration of ACG in each layer of the ear was measured after 72 hours. The blood and various organs were analyzed by high pressure wave chromatography (HPLC) for the concentration and (ACV) concentration to assess the penetration of the body containing the accelerator and the distribution of various organs. < Please read the precautions on the back before filling the nest page). Binding. Binding. Printed by the Central Standards Bureau of the Ministry of Economic Affairs and the Engaged Consumer Cooperatives *. This paper size is applicable to the Chinese National Standard (CNS> A4 specifications (210X297 1) 2j9 μ] / 〇2 Therefore " 1 benefit§ table, 2-l as a percutaneous absorption accelerator Chinese herbal medicine (Arteoisiae Capillaris Herba): (essential oi 1); capi 11 in, capi 1 lene, capi 1 lone, capi 1 larin, Nw'capi 1 lene, capi 1 lanol (Qirysantheium): essential oil; ㈠-tx-Bisabolol, 〇 (-Farnesene, Matricin Matricarin, Chanazulene, ie (Cinae Flos) : Essential oil: ㈠-〇c-Pipene, Terpinene, Terpineol, Carvacrol, a-Thujone, ㈠-Camphor, (Saussureae Radix): • Γ ----: ----- installed | (please Read the note $ item on the back before drawing) Essential oil (essential oi 1); Aplotaxene, Costic acid, Costunol ide, Costus lactone 'Dehydrocostus lactone' Dihydrocostus lac1 Phellandrene, α-Ionone, / 3-Ionone, σ-Costol, Camph ^ ie, actone (Valerianae Radix): jHHi (ess ential oil); (+) B «niylisoval« 'ate ^ Bornylacetate' Kessane '㈠-Campehne, (+-)-Liaonene, ot-Twpineol, α-Kessylaicdiioi, cx-fesylalcdiol acetate, Kessanol, Kessoglycol, Valeranwie, Fauer ^ Cryptofauronol 'Kanokonyl acetate' Linalool, / 3-Pi_e, Kandwml, a-Pinoie Mint (Maithae Herba): m (essential oil) :, (-)-ifenthol, Acetyllnenthol, ㈠-Moithone, ㈠-Liaoiene, (+ ) -tethol Puleg (»ie, Piperitoie, Is« Baitiione, Cdnphene, 3-0ctanol, γ-Hexenyi, Penylacetate, a-Pinene,

MentherKXte 經濟部中夬揉率局負工消费合作社印装 (Perillae H^ba): 汾油(essential oil) ·· (-)HPo*illalddiyde、(+)-LUrai«ie、cxHMnene P^i 1 laket(me ^ naginataketxmeN egonaketone 荆 (Schizonepetae Herba) ' 芥 (essential oil) ; (+)-MenthoneN (±)-Henthonel Λ (+)HLieonene ^ (-)-Pulegone (Evodiae Fructus)- 1 ^j^(ess»itial oil) ;Evod«ie _ 本紙張尺度逍用中國國家橾率(CNS > A4规格(210X297公羡) ·_ * 年月Π i / 8an-%j 表於 A9 B9 C9 D9 經濟部中央揉準局貝工消费合作社印«. ! ' ' ' 、‘·片 茴 (Fooiiculi Fructus): 香 (essential oil) ; Anethole'Estragole' (+)-a-Pinene' (+)-Fenchone、(±)-Lieonene、AnisaldeHyde 丁 (Cary«>hylli Flos) *· 香 价油(essential oil) :Eugenol、Eugenol acetate、Eugenol salicylate、 Methy 1 sal icy late、Vani 11 in、/3 -Caryophyl loie、Humulene、 Methyl amyl ketone、Chav i col、a-Ylangene 桉 (Eucalypti Folium): 棄 (essential oil) : 1,8-CineoleN P-Cymene'Terpineol ^ Cuuinal ^ Phelland'al、Pinene 美 6^igae Radix): 遠 精油(essential oil),·Methyl salicylate 志 息苷(saponin) : S«iegin-I、Senegin-II、Senegin-III、S«iegin-IV 花 (Zanthoxyli Fructus): 椒 猜油(essential oil) ; Geraniol、Limonene、Cumic alcohol 細 (Asari H^ba cun Radice): 辛 你由(essential oil) ·· Eucarvone、Safrole、Methyleugenol、Elenicin、 Asaricin、厶-pinene、(+)-bomeol、Croweacin 胡 (Piperis Fructus): 权 11¾(essential oil);㈠-a~Phellandrene、/3-pinene、Linalool 蕺 Qknittuyniae Herba): 菜 价油(essential oil) ; Decanoylacetalddiyde、Hethylnonyl ketone、 Laurinalddiyde 五 味 子 (Sdiizand^e Fructus): 精油(essential oil) ; Htral、oc-Cha«igmie、/3~Cha*igraie、 Chamigroie、Sesquicarene、/3-Chanigrenal 辛 (Hagnoliae Flos) *> 夷 H^Cess^itial oil) ; MethyldiavicolN Caaphor'1,8-cineole ' p-cymoie f··-. (): (請先S讀背面之注$項再行燴袈) % 訂 本紙張尺度逍用中國國家榉準(CNS } A4«L格(210X297公釐) *玉、%州汉( 旅 ji: n A9 B9 C9 D9 表2-3 經濟掌夬揉率局Λ工消费合作社印It 忽 (Lupuli Strobilus) V 布 揞油(ess^itial oil) : α-hunul如e、^-huoulene'Huniladi纽one、 f (Alpiniae Fructus): 仁 (ess^itial oil) : Hootkatwie、Zingiberaie、ZingiboOl、 a-humul«ie 城 (Anomi Senen): 砂 精油(essential oil) : (+)-bomeol ' Bomylacetate'N-'eroldiol 鬱 (Curcumae Tuber): 金 你’由(essential oil) ;Tunoerone、(+)-artunnerone、Zingiberne、 (+) - a -phel lancfr'ene 莪 (Zedoariae Rhizoma): 倍半萜類(Sesquiterpaioid) : Curzerenone、Curdione、Curcolone、 Furanodienone、Furanogerroenone、1,4-cineole、Zed^one、 Curcumol ΰχ (Cyperi Rhizoma): Hi 子 (essential oi 1) ; Cyperol' α-Cyperone' CypereneΛ Cyperotundone' Cyp«x)lone ^ Sugaiolacetate' Kobusone 番 (Croci Stigma): 花 (essential oil) ;Safranal 遠 (Polygalae Radix): 志 皂發(saponin) ;Onjisap〇nin A~G (A=senegin IV)、(B=senegin III)、 frosenegeni、Tenuifol in、Senegenin、 黄 (Astragali Radix): 耆 龙發(saponin) ;Astragaloside I-VIII、Soyasaponin I 牛 (Adiyranthis Radix): 臻 兔發(saponin) :01eanolic acid glycoside 知 (Anenarrhenae Rhizona): 母 兔發(saponin) : Tiaosaponin A-I、Tiaosaponin A-III、Markogenin、 Neogitogaiin glycosides ^ / ττκ^ ___ 2 厂 { ---------裝I (請先H讀背面之注$項再行繪製) 訂 本紙張尺度逋用中國國揉率(CNS ) A4«L格(210X297公釐} Α9 Β9 C9 D9 經濟部中央揉率局貝工消费合作社印装 表2-4 杜 (Houtan Radicis Cw*tex)' 1 單?δ類(Monoterpenoid) ;Oxypaeoniflorin Benzoylpaeoniflorin、 Benzoyloxypaoxiif lorin' Paeonif lwin 甘 (Eio^iorbiae Kansui Radix) *> 二乾類(ditQTene ) ; Kansuinin A、B、、2(H)eoxyingeno卜3-benzoate、 Ingenol-3-(2,4-decadienoate)-20-acetate ^ 20-Deoxy ingeno 1 H5-benzoate 遂 三萜類(triterpene ) ; oc-Luphol、Tirucallol、Euphorbaclienol、 /3-Eiiphorbol 附 (Aconiti Tuber): 子 二辟類(diterpene):舶saconitine、Hypaaiitine、Jesaconitine、 Heopel 1 ine、Kobusine、Pseuctobusine、Telatisine、Songorine、 .Atidine、Napel 1 ine、Heteratisine、Lignanine、Hypognavine、 Atisine ^ Aconitine f (Tragacantha): I 三疮類(triterpene ) ;Tragoside I、Tragoside II 麥 (Ophiopogonis Tuber) η 冬 鬼發(saponin) ; ophiopoqwin A、ophiopooonin B、oriiiwoqc^in C、 ophiopoqonin B’、6phiopoqonin C’、ophiopoqonin D’、 (^liopocKmin D 桃 (Persicae Senen): 仁 三?S類(triterpene ) ; 24-methylenecycloaartanol 升 (Cinicifugae Rhizona): 來 三類(trit〇T3ene ) ;Cii>igaK)l xyloside、12-hydr<wyci«dgenol、 12-hydOxyciBigaK)l xyloside Λ Dahurinol' Isodahurinol ^ 24t)-acet^l isodahurinol' Ciaig^iol 桑 (Mw*i Radicis C«*tex) *. Θ 皮 三給類(triterpoie ) ; ot-aayrinacetate、Betulinic acid 茅 (Laperatde Rhizona): 根 三格類(triterpene ) : CyliruHn、Arundoin、Femenol、Simiarenol、 IsosurbcM'inol ---------{».I (請先閲讀背面之注$項再行飧裝) 訂 本紙張尺度適用t國國家橾率(CNS ) Λ4規格(210X297公簸) 表:3-1MentherKXte Printing and Printing Cooperative of the Ministry of Economic Affairs of the Ministry of Economic Affairs (Perillae H ^ ba): Fen oil (essential oil) · (-) HPo * illalddiyde, (+)-LUrai «ie, cxHMnene P ^ i 1 laket (me ^ naginataketxmeN egonaketone (Schizonepetae Herba) 'Mustard (essential oil); (+)-MenthoneN (±) -Henthonel Λ (+) HLieonene ^ (-)-Pulegone (Evodiae Fructus)-1 ^ j ^ (ess » itial oil); Evod «ie _ This paper scale is free to use the Chinese national rate (CNS> A4 specification (210X297 public envy)) _ * Month Π i / 8an-% j Table A9 B9 C9 D9 Central Ministry of Economics Printed by the quasi-administrative Beigong Consumer Cooperative «. '' ',' Fooiiculi Fructus: essential oil; Anethole'Estragole '(+)-a-Pinene' (+)-Fenchone, (±) -Lieonene, Anisalde Hyde (Cary «> hylli Flos) * Essential oils: Eugenol, Eugenol acetate, Eugenol salicylate, Methy 1 sal icy late, Vani 11 in, / 3 -Caryophyl loie, Humulene, Methyl amyl ketone, Chav i col, a-Ylangene Eucalyptus (Eucalypti Folium): Essential oil: 1,8-CineoleN P-Cym ene'Terpineol ^ Cuuinal ^ Phelland'al, Pinene US 6 ^ igae Radix): essential oil, Methyl salicylate saponin: S «iegin-I, Senegin-II, Senegin-III, S «Iegin-IV flower (Zanthoxyli Fructus): pepper guess oil (essential oil); Geraniol, Limonene, Cumic alcohol fine (Asari H ^ ba cun Radice): Xin Youyou (essential oil) · · Eucarvone, Safrole, Methyleugenol, Elenicin , Asaricin, Do-pinene, (+)-bomeol, Croeacin Fructus (Piperis Fructus): Right 11¾ (essential oil); ㈠-a ~ Phellandrene, / 3-pinene, Linalool 蕺 Qknittuyniae Herba: Vegetable oil (essential oil) ); Decanoylacetalddiyde, Hethylnonyl ketone, Laurinalddiyde Schisandra (Sdiizand ^ e Fructus): essential oil; Htral, oc-Cha «igmie, / 3 ~ Cha * igraie, Chamigroie, Sesquicarene, / 3-Chanigrenal Xin (Hagnoliae Flos) * > Yi H ^ Cess ^ itial oil); MethyldiavicolN Caaphor'1,8-cineole 'p-cymoie f ··-. (): (Please read the note $ item on the back first and then stew)% Book Paper-scale free use of China Beech quasi (CNS} A4 «L grid (210X297mm) * Jade,% Zhouhan (Travel ji: n A9 B9 C9 D9 Table 2-3 Economic control and bureau rate, labor and consumer cooperatives printed It Hu (Lupuli Strobilus) V cloth oil (ess ^ itial oil): α-hunul such as e, ^ -huoulene'Huniladi Newone, f (Alpiniae Fructus): Ren (ess ^ itial oil): Hootkatwie, Zingiberaie, ZingiboOl, a-humul «ie Anomi Senen: Essential oil: (+)-bomeol 'Bomylacetate' N-'eroldiol (Curcumae Tuber): Jin You 'You (essential oil); Tunoerone, (+)-artunnerone, Zingiberne, (+)-a -phel lancfr'ene (Zedoariae Rhizoma): Sesquiterpaioid: Curzerenone, Curdione, Curcolone, Furanodienone, Furanogerroenone, 1,4-cineole, Zed ^ one, Curcumol ΰχ (Cyperi Rhizoma) : Hi sub (essential oi 1); Cyperol 'α-Cyperone' Cyperene Λ Cyperotundone 'Cyp «x) lone ^ Sugaiolacetate' Kobusone (Croci Stigma): Flower (essential oil); Safranal far (Polygalae Radix): Zhi soap hair ( saponin); Onjisap〇nin A ~ G (A = senegin IV), B = senegin III), frosenegeni, Tenuifolin, Senegenin, yellow (Astragali Radix): saponin; Astragaloside I-VIII, Soyasaponin I cow (Adiyranthis Radix): saponin: 01eanolic acid glycoside (Anenarrhenae Rhizona): Female rabbit hair (saponin): Tiaosaponin AI, Tiaosaponin A-III, Markogenin, Neogitogaiin glycosides ^ / ττκ ^ ___ 2 Factory {--------- Install I (please read the back of H first Note $ item is drawn again) The size of the paper used in this book is the Chinese rubbing rate (CNS) A4 «L grid (210X297mm) Α9 Β9 C9 D9 Printed Table 2-4 of the Beigong Consumer Cooperative of the Central Rubbing Rate Bureau of the Ministry of Economic Affairs (Houtan Radicis Cw * tex) '1 Single? Δ (Monoterpenoid); Oxypaeoniflorin Benzoylpaeoniflorin, Benzoyloxypaoxiif lorin' Paeonif lwin Gan (Eio ^ iorbiae Kansui Radix) * > Class II (ditQTene); Kansuinin A, B, 2 (H) eoxyingeno bu 3-benzoate, Ingenol-3- (2,4-decadienoate) -20-acetate ^ 20-Deoxy ingeno 1 H5-benzoate triterpene; oc-Luphol, Tirucallol, Euphorbaclienol, / 3-Eiiphorbol with (Aconi ti Tuber): diterpene: disapenine, Hypaiaitine, Jesaconitine, Heopel 1 ine, Kobusine, Pseuctobusine, Telatisine, Songorine, .Atidine, Napel 1 ine, Heteratisine, Lignanine, Hypognavine, Atisine ^ Aconi ): Triterpene I; Tragoside I, Tragoside II wheat (Ophiopogonis Tuber) η winter ghost hair (saponin); ophiopoqwin A, ophiopooonin B, oriiiwoqc ^ in C, ophiopoqonin B ', 6phiopoqonin C', ophiopoqon , (^ LiopocKmin D Peach (Persicae Senen): Rensan? Class S (triterpene); 24-methylenecycloaartanol l (Cinicifugae Rhizona): To three types (trit〇T3ene); Cii > igaK) l xyloside, 12-hydr < wyci «dgenol, 12-hydOxyciBigaK) l xyloside ^ Dahurinol 'Is 24t) -acet ^ l isodahurinol 'Ciaig ^ iol mulberry (Mw * i Radicis C «* tex) *. Θ triterpoie; ot-aayrinacetate, Betulinic acid grass (Laperatde Rhizona): root trigeminal ( triterpene): CyliruHn, Arundoin, Femenol, Simiarenol, IsosurbcM'inol --------- {». I (please read the note $ item on the back first and then install it) Rate (CNS) Λ4 specifications (210X297 public) Table: 3-1

-i « &lt; 1 --'lJ A9 B9 C9 D9, «.濟部中央揉率局i消费合作社印«. 甘 (Clycyrrhizae Radix): 萆 三乾顛皂苷(triterpoie sapoiin) : Glycyrrhizin、glycyrrhetinic acid、 18-/3-glycyrrhetinic acid 1 (Zingiberis Rhizona): 精油(essential oil) : ct-Pinene、/3-Myrcene、Cineole 大 (Zizyphi Fructus): 三萜類(triterpenoid) :01eanolic acid、Ursolic acid t 皂苷(saponin) ; Zizyphus saponin I、Zizyphus saponin II、Zizyphus saponin III' Jujuboside B'inaslinic acid' Betulonic acid 皂 (Gleditsia sinensis Lam.): 三锆類龙苷(triterp^e sapiMiin) :Gledinin、Gleditschia Saponin 角 鞣質(Tannins) : Cetylalc^ol、Nwia6osane、Stigeast^ol、Sitosterol 茯 (Hoelen) 芩 三锆類息登(triterpene saponin) : Eburicoic add、Dehydroeburicoic acid、3冷-O^abetylddiydO tumulosic acid、Ergosteroi、 3&gt;3-〇-acetyltuiulosic acid 芍 (paemiae radix): 單¢1 類配雄技(wMioterpaie glycoside) : Albiflorin、Paeonif lcrin、 Oxypaeoniflorin' Paeon if lor igaioneN B«izoylpae〇nif lorin 藥 鞣質(Tannins) : Tetraundeca、gal loylglucose、(+)-Catechin、 Procyanidin B-l 桂 (Cinnaaoni Cortex et caul is): (essential oil) ;Cinnaaaldehycle^Cinnaiiyl acetate ^Phenylpropyl acetate 皮 鞣質(Tannins) : Cinnzeylanol、Cinnzeylanine、Anhydrocinnzeylanine、 Cinncassiol A' Cinncassiol B ' Cinncassiol Cl ^ Procyanidin C-l' Cinncassiol A 19~«onoacetate、Cinncassiol C3、Cinncassiol D1、 Cinncassiol A 19-〇-glucoside &gt; Cinncassiol D1 19-〇-glucoside ^ Cinncassiol B 19-0-glucoside' Cinncassiol D2 19-0-glucoside' Cinncassiol Cl 19-0-glucoside'Anhydrocinnzeylanol 'Gallic acid Cinncassiol D4^Cinncassiol E^Cinncassiol ^^Cinncassiol D2^ Cinncassiol D3' Procyanidin B-2 ^ Procyanidin B-5N Apigenin 3,7-dirhamoside N Protocatechuic acidN (-)HEpicatechin (請先Η請背面之注$項再行飧裝) 本紙張尺度遑用中國國家揉率(CNS ) A相I格(210X297公釐) ρττ- Ά〈'.· . A1 .1 ‘ 订 D9 £ ^ Bfj Ιι ββ表3-2 ;j- 經濟部中夬揉率局貝工消费合作社印装 小 豆 蔻 (CardaiKXDi Fructus): 猜油(essoitial oij) ; (+)-ot-Terpinyl acetate、l,8-Cineole、Sabinene Uaonoie、(+)-&lt;x-Terpineol 朮 (Atractylodis Rhizona): 精油(essoitial oil) ;Atractyl(«、Eudesina~4(14)、Atractylenolide I、 Hinesol、Atractylenolide II'Atractylenolide III、Eiemol、 3&gt;3-acetoxyatractylonN 3/3-hydOxyatractylonΛ ^-eudesinol' Atractylodine ^ Atractylcxiinol' acetylatractylodinol' 7(ll)-Oien-8-&lt;Mie 當 (Angel icae Sinensis radix): 歸 (essoitial oil) ; Butyliden^&gt;hthalide' A2.4~dihydOphthalic anhydride'n-Val«x&gt;phenone-0^carboxylie acid 人 (Ginseng Radix): 未 矣發類(saponin) ;Heptaedeca-l~oi-4、6-Dihn-3,9-^diol panaxydol、 20-glucoginsenoside-Rf' Qioline' /3-Sitosterol glucosideN Ginsenoside-Rx(x=〇,al,a2,bl,b2,b3,c,d,e,f,gl,g2,hl)、 Nicotinic acid、召-Sitosterol、/3-Eiemene' Panaxynol、 陳 (Citri Exocarpium): 皮 价A (essential oil) ; d-linonene、Linalool、Citral、Hesperidin、 Neohesperidin、Naringin、Poncirin、Umbel 1 iferone、Auraptene、 gijroptene、Imperatorin、Isoinperatorin、Isoponciaarine、 (-)-Synerfirine'Citric acid 黄 (Scutellariae Radix): 本 责酮類(flavonoid) ; Baicalin、Stigmasterol、Wogoin glucuronide、 Wogonin、Baicalein、Oroxylin A、Oroxylin A glucuronide、 5,8-DihydOxy-6,7-diBethoxy-flav(Mie' Skullcap-Flavon I' 5,7,4’-Trihydroxy-8-Bethoxy flavone、Scullcap-Flavwi II、 5,7,2’,6’-Tetrahydroxy flavone'Canpest^ol、召-Sitosterol、 Kogan^ananin 柴 (Bupleuri Radix) *· 胡 皂芬類(sapoiin) ·· Saikosapwiin a、c、d · Oleic acid、a-Spinasterol、 △7-StigBasterol、Linolenic acid、Lignoceric acid、Adonitol、 Saikogenin F、E、G · Longi印inogenin lignoceric acid、 Palmitic acid、Angel icin、Stearic acid 川 (Ligustici Rhizona): 芎 (essential oil) :Cnidiua lactone、Ferulic acid、Cnidilide、 Neocnidilide (請先S讀背面之注$項再行蜻裝) -紙張尺度適用中國«家揉率(CNS &gt; A4规格(210X297公釐) 相j A9 B9 C9 D9-i «&lt; 1-'lJ A9 B9 C9 D9,«. Ministry of Economic Affairs, Central Consumer Affairs Bureau, i Consumer Cooperative Seal «. Gan (Clycyrrhizae Radix): Triterpoie sapoiin: Glycyrrhizin, glycyrrhetinic acid, 18- / 3-glycyrrhetinic acid 1 (Zingiberis Rhizona): Essential oil: ct-Pinene, / 3-Myrcene, Cineole (Zizyphi Fructus): Triterpenoids: 01eanolic acid, Ursolic acid t saponin ( saponin); Zizyphus saponin I, Zizyphus saponin II, Zizyphus saponin III 'Jujuboside B'inaslinic acid' Betulonic acid soap (Gleditsia sinensis Lam.): triterp ^ e sapiMiin: Gledinin, Gleditschia Saponin (Tannins): Cetylalc ^ ol, Nwia6osane, Stigeast ^ ol, Sitosterol Hoelen Triterpene saponin: Eburicoic add, Dehydroeburicoic acid, 3 cold-O ^ abetylddiydO tumulosic acid, Ergoster3, Ergosteroi -〇-acetyltuiulosic acid pea (paemiae radix): single ¢ 1 class with male skills (wMioterpaie glycoside): Albiflorin, Paeonif lcrin, Oxypaeoniflorin 'Paeon if lor igaioneN B «izoylpae〇nif lorin Tannins: Tetraundeca, gal loylglucose, (+)-Catechin, Procyanidin Bl (Cinnaaoni Cortex et caul is): (essential oil); Cinnaaaldehycle ^ Cinnaiiyl acetate ^ Phenylpropyl acetate Tannins: Cinnzeylanol, Cinnzeylanine, Anhydrocinnzeylanine, Cinncassiol A 'Cinncassiol B' Cinncassiol Cl ^ Procyanidin Cl 'Cinncassiol A 19 ~ «onoacetate, Cinncassiol C3, Cinncassiol D1, Cinncassiolc 19 &D; 〇-glucoside ^ Cinncassiol B 19-0-glucoside 'Cinncassiol D2 19-0-glucoside' Cinncassiol Cl 19-0-glucoside'Anhydrocinnzeylanol 'Gallic acid Cinncassiol D4 ^ Cinncassiol E ^ Cinncassiol ^^ Cinncassiol D2 ^ Cinncassiol 2 ^ Procyanidin B-5N Apigenin 3,7-dirhamoside N Protocatechuic acidN (-) HEpicatechin (please note the item on the back first, and then install it) This paper size is not used in China National Rubbing Rate (CNS) A phase I grid (210X297 mm) ρττ- Ά <'.. .A1 .1' Order D9 £ ^ Bfj Ιι ββ Table 3-2 ; J- Printed Cardamom (CardaiKXDi Fructus) by the Belgian Consumer Cooperative of the Ministry of Economic Affairs of the Ministry of Economic Affairs: guess oil (essoitial oij); (+)-ot-Terpinyl acetate, l, 8-Cineole, Sabinene Uaonoie, (+ )-&lt; x-Terpineol (Atractylodis Rhizona): essential oil (essoitial oil); Atractyl («, Eudesina ~ 4 (14), Atractylenolide I, Hinesol, Atractylenolide II'Atractylenolide III, Eiemol, 3 &gt; 3-acetoxyatractylonN 3 / 3-hydOxyatractylonΛ ^ -eudesinol 'Atractylodine ^ Atractylcxiinol' acetylatractylodinol '7 (ll) -Oien-8- &lt; Mie Dang (Angel icae Sinensis radix): Gui (essoitial oil); Butyliden ^ &gt; hthalide'Aic ~ di2.4 anhydride'n-Val «x &gt; phenone-0 ^ carboxylie acid person (Ginseng Radix): saponin; Heptaedeca-l ~ oi-4, 6-Dihn-3, 9- ^ diol panaxydol, 20- glucoginsenoside-Rf 'Qioline' / 3-Sitosterol glucosideN Ginsenoside-Rx (x = 〇, al, a2, bl, b2, b3, c, d, e, f, gl, g2, hl), Nicotinic acid, Zhao-Sitosterol , / 3-Eiemene 'Panaxynol, Chen (Citri Exocarpium): Skin price A (essential oil); d-li nonene, Linalool, Citral, Hesperidin, Neohesperidin, Naringin, Poncirin, Umbel 1 iferone, Auraptene, gijroptene, Imperatorin, Isoinperatorin, Isoponciaarine, (-)-Synerfirine'Citric acid yellow (Scutellariae Radix): ketones Baicalin, Stigmasterol, Wogoin glucuronide, Wogonin, Baicalein, Oroxylin A, Oroxylin A glucuronide, 5,8-DihydOxy-6,7-diBethoxy-flav (Mie 'Skullcap-Flavon I' 5,7,4'-Trihydroxy-8- Bethoxy flavone, Scullcap-Flavwi II, 5,7,2 ', 6'-Tetrahydroxy flavone'Canpest ^ ol, Zhao-Sitosterol, Kogan ^ ananin Chai (Bupleuri Radix) * Sapoiin * Saikosapwiin a , C, d · Oleic acid, a-Spinasterol, △ 7-StigBasterol, Linolenic acid, Lignoceric acid, Adonitol, Saikogenin F, E, G · Longi Indiainogenin lignoceric acid, Palmitic acid, Angel icin, Stearic acid Sichuan (Ligustici Rhizona ): Essential oil: Cnidiua lactone, Ferulic acid, Cnidilide, Neocnidilide (please read the note $ item on the back and then do the dragon suit)-paper The Zhang scale applies to China's «home rubbing rate (CNS & A4 specification (210X297mm) phase j A9 B9 C9 D9

j * 地 (Rdunanniae Radix et Hiiz(»a): 黄 黄明類(f lavonoid) : Rdinannoside A、B * Aucubin、Nel ittoside、 Rehnannioside ^ LenuorideCatalpol 半 (Pinelliae Tub»*) ϊ Honog如tisic acid glucoside、3,4-Dihyd*〇3〇d)aizalddiyde、 tk»og«itisic acid、3,4H)ihydroxyb«izalddiyde digkicoside、 召-Sitost«Olglucoside、E^edrine、Qwl ine、/3-Sitosterol X 欠 (Rhei Rhizona) * 蔥K^(anthraquinone) : Chrysor^ianol、Aloe-eeodin、Hiysciwi、Emodin、 Chrysoriianol 1-glucoside' Chrysophanol 8-glucoside ^ Rhein' Aloe-emodin-8-glucoside ^ Citreorosein' Physcion-8-glucoside' Emodin-l-glucoside ^ Enodin-8-glucoside ^ Rhein-8-glucoside ' Rhein-8-(6*^oxai-yl)glucoside、S^tinoside A、B、C、D、E、F (請先《讀背Λ之注$項再行繪装) 黄 琢質(Tannins) : (-)-Epicatechin、(-)-pi&gt;icatediin-3-0~gallate、 Procyanidin B-l 3-0-gal late' (+)-Catechin 厚 朴 枳 實 桔 梗 澤 (Magnoliae Cortot): essential oil) : /3-Eudesnol、ot-Pinene、卢-Pinene、Caaphene、 Bornylacetate' Cary&lt;»&gt;hyl leneepoxide ^ Cryptoaeridiol' Liawiene Magnolol、Honddol、Itoocurarine、Hagnoflorine、Anonaii Liriodenine、Salicifoline、oc-£ude9nol、Hidielarbine odenine、Salicifoline ^jrarine 、ot-Eud ideanol line (Citri Fructus): 精油(essential oil) : d-Liffl〇n«ie、Linalool、Citral、(其他同殊皮) ^latycodi Radix): 息皆類(saponin) ; Platycodin A、C、D、D2 »Polygalacin D、D2 »Inul in _a-Spinasterol' α-Spinasterol glucoside ^ Stigeiast-7-enoi'j * ground (Rdunanniae Radix et Hiiz (»a): f lavonoid): Rdinannoside A, B * Aucubin, Nel ittoside, Rehnannioside ^ LenuorideCatalpol half (Pinelliae Tub» *) ϊ Honog such as tisic acid glucoside, 3 , 4-Dihyd * 〇3〇d) aizalddiyde, tk »og« itisic acid, 3,4H) ihydroxyb «izalddiyde digkicoside, zhao-Sitost« Olglucoside, E ^ edrine, Qwl ine, / 3-Sitosterol X owed (Rhei Rhizona ) * Scallion K ^ (anthraquinone): Chrysor ^ ianol, Aloe-eeodin, Hiysciwi, Emodin, Chrysoriianol 1-glucoside 'Chrysophanol 8-glucoside ^ Rhein' Aloe-emodin-8-glucoside ^ Citreorosein 'Physcion-8-glucoside' Emodin -l-glucoside ^ Enodin-8-glucoside ^ Rhein-8-glucoside 'Rhein-8- (6 * ^ oxai-yl) glucoside, S ^ tinoside A, B, C, D, E, F (please read (Notes on the back Λ $ items will be painted again) Huang Zhuanzhi (Tannins): (-)-Epicatechin, (-)-pi &gt; icatediin-3-0 ~ gallate, Procyanidin Bl 3-0-gal late '(+)-Catechin Magnoliae Cortot: essential oil): / 3-Eudesnol, ot-Pinene, Lu-Pinene, Caaphene Bornylacetate 'Cary &lt; »&gt; hyl leneepoxide ^ Cryptoaeridiol' Liawiene Magnolol, Honddol, Itoocurarine, Hagnoflorine, Anonaii Liriodenine, Salicifoline, oc- £ ude9nol, Hidielarbine odenine, Salicifoline ^ jraudine (ot) essential oil): d-Liffl〇n «ie, Linalool, Citral, (other common leather) ^ latycodi Radix): Saponin; Platycodin A, C, D, D2» Polygalacin D, D2 »Inul in _a-Spinasterol 'α-Spinasterol glucoside ^ Stigeiast-7-enoi'

Betulin (Alisnatis Rhiz(»Da): 鍾濟部中.央橾率局貝工消费合作社印氧 瀉 肉 主 蔻 白 豆 蔻 三格類(triterpene ) ·· Alisol A、B · Lecithin、Alisol B eonoacetate Alisol C nonoacetate ^ Alisol A nonoacetateΛ Choi ine ^ (Hyristicae Semen) · ίίϋ (essential 〇Π.).ί (+)-Caiarfiene ^ (+)Linalool ^ Safrole ' Eug^iol &gt; Hyristicin' (+)-a-Pinene' (+)-^3-Pinene &gt; (+)-Limonaie' Xylan (+)-Borneol、Geraniol、α-Terpineol、Myristin olein、Pentosan Furfural、Pectin、Lipase、Sapbnin (Anoni Cardancni Fructus): (essential oil) ; (+)-Caephor ' (+)-^orneol &gt; Huaulaie epoxide' 1,8-Cineole' α-Pinene' /3-Pinene' Caryophyllene' Myrcene ^Betulin (Alisnatis Rhiz (»Da): Zhongji Ministry of Central and Central Bureau of the Central Bureau of the Belgian Consumption Cooperative Society of Oxygen Diarrhea Cardamom White Cardamom Triterpene · Alisol A, B · Lecithin, Alisol B eonoacetate Alisol C nonoacetate ^ Alisol A nonoacetateΛ Choi ine ^ (Hyristicae Semen) ίίϋ (essential 〇Π.). ί (+)-Caiarfiene ^ (+) Linalool ^ Safrole 'Eug ^ iol &gt; Hyristicin' (+)-a-Pinene ' (+)-^ 3-Pinene &gt; (+)-Limonaie 'Xylan (+)-Borneol, Geraniol, α-Terpineol, Myristin olein, Pentosan Furfural, Pectin, Lipase, Sapbnin (Anoni Cardancni Fructus): (essential oil) ; (+)-Caephor '(+)-^ orneol &gt; Huaulaie epoxide' 1,8-Cineole 'α-Pinene' / 3-Pinene 'Caryophyllene' Myrcene ^

Babinene、Humulene、Carvone、 本紙張尺度遑用中國«家橾率(CNS &gt; Α4Λ格(210X297公^ 補八 A9 B9 C9 D9 £、ffi會:i 叫 表伞 ::画 經濟部中央揉率局貝工消費合作社印氧 促進劑 溶解 (cal/cm3)^ . . · · 咖性指標 β-Myrcenc 7.91 3.06 aneole 8.36 • b a-Pinene 8.83 2.95 Oleanolic acid 9.95 一b 18-B-GIycynhetinic acid 10.5 2.86 Ursolic acid 10.9 —b Glycyirbizin 12.9 1.32Babinene, Humulene, Carvone, this paper scale use Chinese «Household Rate (CNS &gt; Α4Λ grid (210X297 ^ supplementary eight A9 B9 C9 D9 £, ffi meeting: i call the table umbrella :: draw the Central Rubbing Rate Bureau of the Ministry of Economic Affairs Dissolution of calcined oxygen accelerator (cal / cm3) ^ of Beigong Consumer Cooperatives... · Caffeine index β-Myrcenc 7.91 3.06 aneole 8.36 • b a-Pinene 8.83 2.95 Oleanolic acid 9.95 a b 18-B-GIycynhetinic acid 10.5 2.86 Ursolic acid 10.9 —b Glycyirbizin 12.9 1.32

--------^ 裝| (請先閲讀背面之注意事項再行繪製) -訂 本紙張尺度適用中國國家橾準(CNS ) Α4规格(210Χ297公釐)-------- ^ Pack | (Please read the precautions on the back before drawing)-The size of this paper is applicable to China National Standard (CNS) Α4 specification (210Χ297mm)

Claims (1)

-:w '中請專利範圍 種經皮吸收醫藥组合物,其中包為之 胳克和(Acyc丨ovir*,ACV)、狐克和(Ganciclovir ’0即〇、迪敵依(2’,3'-|^也〇父:^11〇3]*1^,001) 、雷保和(fcbaWriv)、阿曼定(/\mantidine)、 維達有(Vidarabine)令、(^idovudine,ZDV 一者爲主成至ϋ藥引子 / ,及2%-99.95%之經皮吸收赋形劑;其中之藥引 子係選自(〇-藏烯[(Is)-(-) -〇f-pinene]、熊 果酸(Orsolic acid)、甘莩酸(6lycyrr*hizin)、 18-甘草次酸(18-/S-&lt;?ilycyrThetinic acid)、棱 葉素(Cineole)、齊敗果酸(Oleanolic acid)、 (+)-¾烯(《-(+)'pinene);賦形劑係選自聚乙 烯二醇(PEG)、羧酸甲基酯纖維素钠(CMC Na)、 甘油,及次乙基乙二醇Lthylene glycol)。 ,如_請專^收醫藥組合物,其中 至20%之藥引子&quot;7&quot;^^99.95%之經皮 吸收賦形劑;其中之藥引子係選自熊果酸(Ursol ic acid)、(IS) -¾烯[Qs)-(-)-〇i-p:inenc5]、按葉 素(Cineole)、甘草酸(4lycyrrhizin)、齊漱果酸 (〇leanolic acid) 、18~甘草次酸(18-/3-fiflycyrrhetinic acid)、(+)_落烯(a~(+)_pinene );賦形劑係選自聚乙烯二酵(PTO、幾酸甲基酯纖 維素钠(CMC Na )、甘油,及次乙基乙二醇( Ethylene glycol) ° 本紙張尺度適用中國國家標準(CNS &gt;八4规格(2丨0X 297公楚 (請先閱讀背面之注意事項再填寫本頁)-: w's patent application range of percutaneous absorption pharmaceutical composition, which includes gram and (Acyciovir *, ACV), fox and (Ganciclovir '0 is 〇, Di Diyi (2', 3 '-| ^ Also father: ^ 11〇3] * 1 ^, 001), Lei Baohe (fcbaWriv), Omandine (/ \ mantidine), Vidarabine (Vidarabine) order, (^ idovudine, ZDV one Primarily into ϋ medicine primer /, and 2% -99.95% percutaneous absorption excipient; the medicine primer is selected from (〇-Tirene [(Is)-(-) -〇f-pinene], Orsolic acid, glycyrrhizic acid (6lycyrr * hizin), 18-glycyrrhetinic acid (18- / S- &lt;? IlycyrThetinic acid), chlorophyllin (Cineole), oleanolic acid (Oleanolic acid) , (+)-¾ene (《-(+) 'pinene); excipients are selected from polyethylene glycol (PEG), carboxymethyl cellulose sodium (CMC Na), glycerin, and hypoethyl Ethylene glycol (Lthylene glycol). For example, please collect the pharmaceutical composition in which up to 20% of the drug primer &quot; 7 &quot; ^^ 99.95% percutaneous absorption excipient; wherein the drug primer is selected from bearberry Acid (Ursol ic acid), (IS) -¾ene [Qs)-(-)-〇ip: inenc5], Cineole, Glycyrrhizin (4lycyrrh izin), 〇leanolic acid (18- / 3-fiflycyrrhetinic acid), (+) _ falling ene (a ~ (+) _ pinene); the excipient is selected from polyethylene di Fermentation (PTO, sodium methyl cellulose acetate (CMC Na), glycerin, and Ethylene glycol) ° This paper scale is applicable to the Chinese National Standard (CNS &gt; 8 4 specifications (2 丨 0X 297 Gong Chu (please read the notes on the back before filling this page) 經濟部中央標準局員工消費合作社印製Printed by the Staff Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs Α8 Β8 C8 D8 六、申請專利範圍 ........ .考f令tL· 3· —種含藥引予之局部醫藥組合物,其中至30 克和(Acyclovir,ACV)、脈克和(tranciclovir ,01^)、迪敵依(2',3*-[)1€|6(^111〇8^,001) 、雷保和(Ribaviriv)、阿曼定(4mantidine)、 維達項(Vidarabine)、携教^斑糾由網* ZDV 一者爲主成^引子 4 ^1^99.95%之經皮吸收賦形劑;其中之藥引 子係選自(1S)-^烯[(ls)-(-)-〇f-pinene]、熊 果酸(Ursolic acid)、18-甘草次酸(18-召-^ycyrrhetinic acid)、棱葉素(Cineole)、甘萆 酸(&amp;lyc:;yrrhizin)、齊敗果酸 Wleanolic acid) 、(+)-藏歸(〇?-(+)十丨1^聰);賦形劑係選自聚乙 烯二酵(PEG)、羧酸甲基酯纖維素钠(CMC Na)、 甘油,及次乙基乙二醇(B thy 1 ene g 1 yco 1)。 4·如中請專利葩園第3項之局部醫藥組合物,係包括軟 膏劑、懸浮劑、凝膠劑、溶液劑、喰霧劑、貼劑 局部投藥製劑。 % 經濟部中央標準局員工消費合作'社印製 (請先閱讀背面之注意事項再填寫本f)Α8 Β8 C8 D8 六 、 Apply for patent scope ........ fling tL · 3 · -a local medicinal composition with drug introduction, of which to 30 grams and (Acyclovir, ACV), pulse grams And (tranciclovir, 01 ^), Didiyi (2 ', 3 *-[) 1 € | 6 (^ 111〇8 ^, 001), Ribaviriv, Amanding (4mantidine), Vida (Vidarabine), Carrying Teaching ^ Spot Correction Younet * ZDV is the main one ^ Primer 4 ^ 1 ^ 99.95% percutaneous absorption excipient; the drug primer is selected from (1S)-^ ene [(ls )-(-)-〇f-pinene], Ursolic acid, 18-glycyrrhetinic acid (18- 召-^ ycyrrhetinic acid), Cineole, &amp; lycic acid (&amp;lyc:; yrrhizin), Wleanolic acid), (+)-Zanggui (〇?-(+) 10 ~ 1 ^ Cong); the excipients are selected from polyethylene dizyme (PEG), carboxylic acid methyl Ester cellulose sodium (CMC Na), glycerin, and ethylene glycol (B thy 1 ene g 1 yco 1). 4. The topical medicinal composition according to Item 3 of the Chinese Patent Proposal includes ointments, suspensions, gels, solutions, nebulizers, and patches. Topical administration preparations. % Printed by the Employee Consumption Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the precautions on the back before filling in this f) _1 (CNS ) A4規格(210X 297公釐)_1 (CNS) A4 specification (210X 297mm)
TW83100632A 1994-01-25 1994-01-25 Method for manufacturing acyclovir transdermal delivery TW297771B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW83100632A TW297771B (en) 1994-01-25 1994-01-25 Method for manufacturing acyclovir transdermal delivery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW83100632A TW297771B (en) 1994-01-25 1994-01-25 Method for manufacturing acyclovir transdermal delivery

Publications (1)

Publication Number Publication Date
TW297771B true TW297771B (en) 1997-02-11

Family

ID=51565418

Family Applications (1)

Application Number Title Priority Date Filing Date
TW83100632A TW297771B (en) 1994-01-25 1994-01-25 Method for manufacturing acyclovir transdermal delivery

Country Status (1)

Country Link
TW (1) TW297771B (en)

Similar Documents

Publication Publication Date Title
CN100512858C (en) Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases
CN102302673B (en) Traditional Chinese medicine compound preparation for preventing and treating diabetic nephropathy (DN)
Li Chinese herbal medicine
CN1931277B (en) Osteoarthrosis treating Chinese medicine composition and its preparation process
CN105497261A (en) Matrix of patch for external use and patch and sleeping-aid patch made from matrix
CN103071134B (en) External preparation for treating rheumatic arthrodynia and traumatic pain and swelling and preparation method thereof
CN105267559B (en) A kind of drug and preparation method thereof for treating diabete peripheral herve pathology
CN109528917B (en) Korean medicinal composition for treating rheumatoid arthritis and preparation method of cream thereof
TW297771B (en) Method for manufacturing acyclovir transdermal delivery
CN104940513A (en) Pharmaceutical composition for treating menopause syndrome
CN102048913B (en) Traditional Chinese medicine preparation for treating climacteric syndrome and preparation method thereof
CN102293985A (en) Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof
CN103860977B (en) A kind of pharmaceutical composition for the treatment of dermatitis
CN103054991B (en) Traditional Chinese medicine composition for treating lower abdominal discomfort, as well as preparation method and use thereof
CN1321632C (en) Compound saussurea involucrata capsule and its preparation process
DE202007002146U1 (en) Herbal composition, useful to treat, e.g. cancer, comprises extracts of Ginseng flowers and roots, Astragalus, Atractylodes, Angelica, Citrus reticulata, Bupleurum chinenis, sweet woodrose and Cimicifuga root
CN101897753A (en) Traditional Chinese medicine for treating coronary disease and preparation method thereof
CN103356971A (en) Traditional Chinese medicine composition capable of substantially improving human immunity and preparation method thereof
CN104873714A (en) Menopausal woman syndrome treatment kidney-tonifying and wind evil dispelling climacteric prescription preparation method
CN104127688A (en) Application of traditional Chinese medicine external-use plaster composition in preparation of drug used for preventing, relieving and/or treating osteoarticular diseases
CN105343847A (en) Traditional Chinese medicine composition for treating eczema containing folium artemisiae argyi and preparing method thereof
CN1129573A (en) Antiviral Drug Acyclovir Percutaneous Absorption Preparation
CN104491318A (en) Traditional Chinese preparation used for treating asthma and preparation method of traditional Chinese preparation
CN103990023A (en) Semen citri reticulatae sperm activating medicament and preparation method thereof
CN113041254B (en) Chinese medicinal composition comprising herba Goodyearae Repentis and its preparation method

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent